UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM
10-Q
 
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Quarter Ended JuneSeptember 30, 2023
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number:
814-01294
 
 
SCP Private Credit Income BDC LLC
(Exact name of registrant as specified in its charter)
 
Delaware
 
83-0634992
(State of Incorporation)
 
(I.R.S. Employer
Identification No.)
500 Park Avenue
New York, N.Y.
 
10022
(Address of principal executive offices)
 
(Zip Code)
(212) 993-1670
(Registrant’s telephone number, including area code)
 
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
 
Title of Each Class
 
Trading
Symbol
 
Name of Each Exchange
on Which Registered
N/A
 
N/A
 
N/A
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
Large accelerated filer   Accelerated filer 
Non-accelerated
filer
   Smaller Reporting company 
Emerging growth company    
If an emerging growth company, indicate by check mark if the
registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of
the
Exchange Act).    Yes  ☐    No  
As of JuneSeptember 30, 2023, there was no established public market for the registrant’s units. The issuer had 25,190,25326,710,775 units outstanding as of August 4,November 3, 2023.
 
 
 


SCP PRIVATE CREDIT INCOME BDC LLC

FORM 10-Q FOR THE PERIOD ENDED JUNESEPTEMBER 30, 2023

TABLE OF CONTENTS

 

  Index  Page
No.
 

PART I.

 FINANCIAL INFORMATION  

Item 1.

 Financial Statements  
 Consolidated Statements of Assets and Liabilities as of JuneSeptember 30, 2023 (unaudited) and December 31, 2022   3 
 Consolidated Statements of Operations for the three and sixnine months ended JuneSeptember 30, 2023 (unaudited) and the three and sixnine months ended JuneSeptember 30, 2022 (unaudited)   4 
 Consolidated Statements of Changes in Unitholders’ Capital for the three and sixnine months ended JuneSeptember 30, 2023 (unaudited) and the three and sixnine months ended JuneSeptember 30, 2022 (unaudited)   5 
 Consolidated Statements of Cash Flows for the sixnine months ended JuneSeptember 30, 2023 (unaudited) and the sixnine months ended JuneSeptember 30, 2022 (unaudited)   6 
 Consolidated Schedule of Investments as of JuneSeptember 30, 2023 (unaudited)   7 
 Consolidated Schedule of Investments as of December 31, 2022   11 
 Notes to Consolidated Financial Statements (unaudited)   14 
 Report of Independent Registered Public Accounting Firm   31 

Item 2.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations   32 

Item 3.

 Quantitative and Qualitative Disclosures About Market Risk   4344 

Item 4.

 Controls and Procedures   44 

PART II.

 OTHER INFORMATION  

Item 1.

 Legal Proceedings   4445 

Item 1a.

 Risk Factors   4445 

Item 2.

 Unregistered Sales of Equity Securities, and Use of Proceeds, and Issuer Purchases of Equity Securities   4547 

Item 3.

 Defaults Upon Senior Securities   4547 

Item 4.

 Mine Safety Disclosures   4547 

Item 5.

 Other Information   4548 

Item 6.

 Exhibits   4649 

SIGNATURES

   4750 

 

2


PART I. FINANCIAL INFORMATION
In this Quarterly Report, “Company”, “we”, “us”, and “our” refer to SCP Private Credit Income BDC LLC unless the context states otherwise.
Item 1. Financial Statements
SCP Private Credit Income BDC LLC
Consolidated Statements of Assets and Liabilities
(in thousands, except unit amounts)
 
   
June 30, 2023
(unaudited)
   
December 31,
2022
 
Assets
          
Investments at fair value:          
Companies less than 5% owned (cost: $505,230 and $529,070, respectively)  $509,719   $532,895 
Companies 5% to 25% owned (
cost: $
21,595 and $0, respectively)
   12,750    —   
Cash   13,060    16,697 
Interest receivable   3,625    3,647 
Receivable for investments sold   99    —   
Prepaid expenses   86    22 
           
Total assets
  $539,339   $553,261 
           
Liabilities
          
Revolving credit facility due December 2023 (the “SPV Facility”) ($236,500 and $267,726 face amounts, respectively, reported net of unamortized debt issuance costs of $700 and $1,392, respectively. See note 5)  $235,800   $266,334 
Revolving credit facility due December 2023 (the “Subscription Facility”) ($26,800 and $70,400 face amounts, respectively, reported net of unamortized debt issuance costs of $115 and $185, respectively. See note 5)   26,685    70,215 
Distributions payable   —      10,825 
Management fee payable (see note 3)   2,136    519 
Incentive fee payable (see note 3)   2,039    4,025 
Administration fee payable (see note 3)   105    108 
Interest payable (see note 5)   4,731    4,041 
Other liabilities and accrued expenses   617    940 
           
Total liabilities
  $272,113   $357,007 
           
Commitments and contingencies (see note 6)        
Unitholders’ Capital
          
Common Unitholders’ capital (25,190,253 and 18,992,563 units, respectively, issued and outstanding)   261,160    196,160 
Accumulated distributable earnings   6,066    94 
           
Total unitholders’ capital
  $267,226   $196,254 
           
Total liabilities and unitholders’ capital
  $539,339   $553,261 
           
Net asset value per unit
  $10.61   $10.33 
           
   
September 30,
2023
(unaudited)
   
December 31,
2022
 
Assets
          
Investments at fair value:
          
Companies less than 5% owned (cost: $497,210 and $529,070, respectively)
  $500,654   $532,895 
Companies 5% to 25% owned (cost: $21,469 and $0, respectively)
   13,565    —  
Cash
   14,989    16,697 
Interest receiva
b
le
   3,845    3,647 
Receivable for investments sold
   72    —  
Prepaid expenses
   54    22 
   
 
 
   
 
 
 
Total assets
  $533,179   $553,261 
   
 
 
   
 
 
 
Liabilities
          
Revolving credit facility due December 2023 (the “SPV Facility”) ($223,800 and $267,726 face amounts, respectively, reported net of unamortized debt issuance costs of $348 and $1,392, respectively. See note 5)
  $223,452   $266,334 
Revolving credit facility due December 2023 (the “Subscription Facility”) ($30,000 and $70,400 face amounts, respectively, reported net of unamortized debt issuance costs of $57 and $185, respectively. See note 5)
   29,943    70,215 
Distributions payable
   —     10,825 
Management fee payable (see note 3)
   3,238    519 
Incentive fee payable (see note 3)
   3,325    4,025 
Administration fee payable (see note 3)
   105    108 
Interest payable (see note 5)
   4,670    4,041 
Other liabilities and accrued expenses
   473    940 
   
 
 
   
 
 
 
Total liabilities
  $265,206   $357,007 
   
 
 
   
 
 
 
Commitments and contingencies (see note 6)
        
Unitholders’ Capital
          
Common Unitholders’ capital (25,190,253 and 18,992,563 units, respectively, issued and outstanding)
   261,160    196,160 
Accumulated distributable earnings
   6,813    94 
   
 
 
   
 
 
 
Total unitholders’ capital
  $267,973   $196,254 
   
 
 
   
 
 
 
Total liabilities and unitholders’ capital
  $533,179   $553,261 
   
 
 
   
 
 
 
Net asset value per unit
  $10.64   $10.33 
   
 
 
   
 
 
 
See notes to consolidated financial statements.
 
3

SCP Private Credit Income BDC LLC
Consolidated Statement of Operations (unaudited)
(in thousands, except unit amounts)
 
   
Three months ended
  
Six months ended
 
   
June 30, 2023
  
June 30, 2022
  
June 30, 2023
  
June 30, 2022
 
Investment Income:
     
Interest:     
Companies less than 5% owned ,,  $15,248  $9,573  $29,636  $18,095 
Other income:     
Companies less than 5% owned   63   45   467   170 
                 
Total investment income   15,311   9,618   30,103   18,265 
                 
Expenses:
     
Management fees (see note 3)  $1,078  $889  $2,136  $1,760 
Incentive fees (see note 3)   1,582   736   1,054   1,586 
Administration fees (see note 3)   105   93   210   181 
Interest and other credit facility expenses (see note 5)   5,694   3,215   12,102   5,804 
Other general and administrative expenses   256   246   522   451 
                 
Total expenses   8,715   5,179   16,024   9,782 
                 
Net investment income  $6,596  $4,439  $14,079  $8,483 
                 
Realized and unrealized gain (loss) on investments:
     
Net realized gain on companies less than 5% owned  $74  $—    $74  $—   
                 
Net change in unrealized gain (loss) on investments:     
Companies less than 5% owned   4,362   (264  (6,110  507 
Companies 5% to 25% owned   (2,071  —     (2,071  —   
                 
Net change in unrealized gain (loss) on investments   2,291   (264  (8,181  507 
                 
Net realized and unrealized gain (loss) on investments   2,365   (264  (8,107  507 
                 
Net Increase in Unitholders’ Capital Resulting From Operations
  $8,961  $4,175  $5,972  $8,990 
                 
Net Income Per Unit
  $0.36  $0.24  $0.25  $0.52 
                 
   
Three months ended
   
Nine months ended
 
   
September 30,
2023
  
September 30,
2022
   
September 30,
2023
  
September 30,
2022
 
Investment Income:
      
Interest:
      
Companies less than 5% owned
  $15,658  $11,749   $45,294  $29,844 
Companies 5% to 25% owned
   13   —     13   —  
Other income:
      
Companies less than 5% owned
   103   48    570   218 
  
 
 
  
 
 
   
 
 
  
 
 
 
Total investment income
   15,774   11,797    45,877   30,062 
  
 
 
  
 
 
   
 
 
  
 
 
 
Expenses:
      
Management fees (see note 3)
  $1,102  $1,010   $3,238  $2,770 
Incentive fees (see note 3)
   1,285   958    2,339   2,544 
Administration fees (see note 3)
   105   102    315   283 
Interest and other credit facility expenses
(s
ee note 5)
   5,722   4,464    17,824   10,268 
Other general and administrative expenses
   172   207    694   658 
  
 
 
  
 
 
   
 
 
  
 
 
 
Total expenses
   8,386   6,741    24,410   16,523 
  
 
 
  
 
 
   
 
 
  
 
 
 
Net investment income
  $7,388  $5,056   $21,467  $13,539 
  
 
 
  
 
 
   
 
 
  
 
 
 
Realized and unrealized gain (loss) on investments:
      
Net realized gain on companies less than 5% owned
  $—   $—    $74  $—  
  
 
 
  
 
 
   
 
 
  
 
 
 
Net change in unrealized gain (loss) on investments:
      
Companies less than 5% owned
   (1,045  372    (7,155  879 
Companies 5% to 25% owned
   941   —     (1,130  —  
  
 
 
  
 
 
   
 
 
  
 
 
 
Net change in unrealized gain (loss) on investments
   (104  372    (8,285  879 
  
 
 
  
 
 
   
 
 
  
 
 
 
Net realized and unrealized gain (loss) on investments
   (104  372    (8,211  879 
  
 
 
  
 
 
   
 
 
  
 
 
 
Net Increase in Unitholders’ Capital Resulting From Operations
  $7,284  $5,428   $13,256  $14,418 
  
 
 
  
 
 
   
 
 
  
 
 
 
Net Income Per Unit
  $0.29  $0.29   $0.55  $0.81 
  
 
 
  
 
 
   
 
 
  
 
 
 
See notes to consolidated financial statements.
 
4

SCP Private Credit Income BDC LLC
Consolidated Statement of Changes
in
Unitholders’ Capital (unaudited)
(in thousands, except unit amounts)
 
   
Three months ended
  
Six months ended
 
   
June 30, 2023
   
June 30, 2022
  
June 30, 2023
  
June 30, 2022
 
Increase (decrease) in unitholders’ capital resulting from operations:
      
Net investment income  $6,596   $4,439  $14,079  $8,483 
Net realized gain   74    —     74   —   
Net change in unrealized gain (loss)   2,291    (264  (8,181  507 
                  
Net increase in unitholders’ capital resulting from operations   8,961    4,175   5,972   8,990 
                  
Distributions to unitholders:
      
From net investment
income
   —      —     —     —   
                  
Increase in unitholders’ capital resulting from capital activity:
      
Contributions   —      20,000   65,000   20,000 
                  
Net increase in unitholders’ capital resulting from capital activity   —      20,000   65,000   20,000 
                  
Total increase in unitholders’ capital   8,961    24,175   70,972   28,990 
Unitholders’ capital, beginning of period   258,265    180,928   196,254   176,113 
                  
Unitholders’ capital, end of period  $267,226   $205,103  $267,226  $205,103 
                  
Capital unit activity
(see note 7):
      
Units issued   —      1,855,288   6,197,690   1,855,288 
                  
Net increase from capital unit activity   —      1,855,288   6,197,690   1,855,288 
                  
   
Three months ended
  
Nine months ended
 
   
September 30,
2023
  
September 30,
2022
  
September 30,
2023
  
September 30,
2022
 
Increase (decrease) in unitholders’ capital resulting from operations:
     
Net investment income
  $7,388  $5,056  $21,467  $13,539 
Net realized gain
   —    —    74   —  
Net change in unrealized gain (loss)
   (104  372   (8,285  879 
  
 
 
  
 
 
  
 
 
  
 
 
 
Net increase in unitholders’ capital resulting from operations
   7,284   5,428   13,256   14,418 
  
 
 
  
 
 
  
 
 
  
 
 
 
Distributions to unitholders:
     
From net investment income
   (6,537  (4,528  (6,537  (4,528
  
 
 
  
 
 
  
 
 
  
 
 
 
Increase in unitholders’ capital resulting from capital activity:
     
Contributions
   —    —    65,000   20,000 
  
 
 
  
 
 
  
 
 
  
 
 
 
Net increase in unitholders’ capital resulting from capital activity
   —    —    65,000   20,000 
  
 
 
  
 
 
  
 
 
  
 
 
 
Total increase in unitholders’ capital
   747   900   71,719   29,890 
Unitholders’ capital, beginning of period
   267,226   205,103   196,254   176,113 
  
 
 
  
 
 
  
 
 
  
 
 
 
Unitholders’ capital, end of period
  $267,973  $206,003  $267,973  $206,003 
  
 
 
  
 
 
  
 
 
  
 
 
 
Capital unit activity
(see note 7):
     
Units issued
   —    —    6,197,690   1,855,288 
  
 
 
  
 
 
  
 
 
  
 
 
 
Net increase from capital unit activity
   —    —    6,197,690   1,855,288 
  
 
 
  
 
 
  
 
 
  
 
 
 
See notes to consolidated financial statements.
 
5

SCP Private Credit Income BDC LLC
Consolidated Statement
of
Cash Flows (unaudited)
(in thousands)
 
   
Six months ended
June 30, 2023
  
Six months ended
June 30, 2022
 
Cash Flows from Operating Activities:
   
Net increase in unitholders’ capital resulting from operations
  $5,972  $8,990 
Adjustments to reconcile net increase in unitholders’ capital resulting from operations to net cash provided by (used in) operating activities:   
Net realized gain on investments   (74   
Net change in unrealized (gain) loss on investments   8,181   (507
(Increase) decrease in operating assets:
   
Purchase of investments   (63,726  (71,185
Net accretion of discount on investments   (1,578  (1,121
Proceeds from disposition of investments   68,597   33,514 
Capitalization of
payment-in-kind
income
   (974  (239
Receivable for investments sold   (99  (78
Interest receivable   22   (376
Prepaid expenses   (64  (74
Increase (decrease) in operating liabilities:
   
Management fee payable   1,617   1,760 
Incentive fee payable   (1,986  (739
Administration fee payable   (3  14 
Interest payable   690   802 
Other liabilities and accrued expenses   (323  264 
Deferred financing costs   794   838 
         
Net Cash Provided by (Used in) Operating Activities
   17,046   (28,137
         
Cash Flows from Financing Activities:
   
Contributions from unitholders   65,000   20,000 
Cash distributions paid   (10,825  (7,277
Proceeds from borrowings   35,168   72,500 
Repayments of borrowings   (110,026  (57,200
         
Net Cash Provided by (Used in) Financing Activities
   (20,683  28,023 
         
NET DECREASE IN CASH
   (3,637  (114
CASH AT BEGINNING OF PERIOD
   16,697   11,181 
         
CASH AT END OF PERIOD
  $13,060  $11,067 
         
Supplemental disclosure of cash flow information:
   
Cash paid for interest  $11,412  $5,002 
         
   
Nine months ended
September 30, 2023
  
Nine months ended
September 30, 2022
 
Cash Flows from Operating Activities:
   
Net increase in unitholders’ capital resulting from operations
  $13,256  $14,418 
Adjustments to reconcile net increase in unitholders’ capital resulting from operations to net cash provided by (used in) operating activities:
   
Net realized gain on investments
   (74  —  
Net change in unrealized (gain) loss on investments
   8,285   (879
Deferred financing costs   1,204   1,275 
(Increase) decrease in operating assets:
   
Purchase of investments
   (82,937  (137,266
Net accretion of discount on investments
   (2,511  (1,779
Proceeds from disposition of investments
   97,423   38,182 
Capitalization of
payment-in-kind
income
   (1,510  (461
Receivable for investments sold
   (72  (120
Interest receivable
   (198  (938
Prepaid expenses
   (32  (39
Increase (decrease) in operating liabilities:
   
Management fee payable
   2,719   2,770 
Incentive fee payable
   (700  219 
Administration fee payable
   (3  23 
Interest payable
   629   1,836 
Other liabilities and accrued expenses
   (467  111 
  
 
 
  
 
 
 
Net Cash Provided by (Used in) Operating Activities
   35,012   (82,648
  
 
 
  
 
 
 
Cash Flows from Financing Activities:
   
Contributions from unitholders
   65,000   20,000 
Cash distributions paid
   (17,362  (11,805
Proceeds from borrowings
   46,768   148,010 
Repayments of borrowings
   (131,126  (73,400
  
 
 
  
 
 
 
Net Cash Provided by (Used in) Financing Activities
   (36,720  82,805 
  
 
 
  
 
 
 
NET INCREASE (DECREASE) IN CASH
   (1,708  157 
CASH AT BEGINNING OF PERIOD
   16,697   11,181 
  
 
 
  
 
 
 
CASH AT END OF PERIOD
  $14,989  $11,338 
  
 
 
  
 
 
 
Supplemental disclosure of cash flow information:
   
Cash paid for interest
  $17,195  $8,432 
  
 
 
  
 
 
 
See notes to consolidated financial statements.
 
6

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited)
June
September 30, 2023
(in thousands, except share/unit amounts)
 
Description
 
 
Industry
 
Spread above
Index
(3)
  
Floor
 
  
Interest

Rate 
(1)
  
Acquisition
Date
  
Maturity

Date
  
Par Amount
  
Cost
  
Fair
Value
 
Bank Debt/Senior Secured Loans — 192.5%
         
ACRES Commercial Mortgage, LLC
(2)
 Diversified Financial Services  S+705   1.00  12.31  12/24/2021   8/21/2028  $ 12,660  $ 12,453  $ 12,660 
Alimera Sciences, Inc.
(2)
 Pharmaceuticals  S+515   4.60  10.32  12/31/2019   5/1/2028   5,893   5,905   5,893 
All State Ag Parts, LLC
(2)
 Trading Companies & Distributors  S+575   1.00  11.25  9/1/2021   9/1/2026   5,191   5,124   5,191 
AmeriMark Intermediate Holdings,
LLC
(2)(5)(11)*
 Internet & Catalog Retail  S+800   1.00  —     7/28/2021   10/15/2026   16,488   15,017   4,516 
AmeriMark Intermediate Holdings, LLC
(5)(11)
 Internet & Catalog Retail  P+475   1.00  13.00  6/16/2023   8/4/2023   408   408   408 
Apex Service Partners, LLC
(2)
 Diversified Consumer Services  S+525   1.00  10.55  11/5/2021   7/31/2025   20,699   20,449   20,699 
Arcutis Biotherapeutics, Inc.
(2)(4)
 Pharmaceuticals  L+745   0.10  12.61  12/22/2021   1/1/2027   24,520   24,847   24,827 
Ardelyx, Inc.
(2)(4)
 Pharmaceuticals  S+795   1.00  13.15  2/23/2022   3/1/2027   3,319   3,346   3,352 
Basic Fun, Inc.
(2)
 Specialty Retail  S+650   1.00  12.04  10/30/2020   10/30/2023   960   959   960 
BayMark Health Services, Inc.
(2)
 Health Care Providers & Services  S+500   1.00  10.50  6/29/2021   6/11/2027   15,782   15,666   15,782 
BridgeBio Pharma, Inc.
(2)(4)
 Biotechnology  —     —     9.00%
(6)
 
  11/17/2021   11/17/2026   14,581   14,523   14,581 
CC SAG Holdings Corp. (Spectrum Automotive)
(2)
 Diversified Consumer Services  S+575   0.75  11.25  6/29/2021   6/29/2028   12,609   12,441   12,609 
Centrexion Therapeutics, Inc. Pharmaceuticals  L+725   2.45  12.41  6/28/2019   1/1/2024   1,246   1,371   1,401 
Cerapedics, Inc.
(2)
 Biotechnology  S+620   2.75  11.37  12/27/2022   1/1/2028   9,698   9,704   9,722 
Enhanced Permanent Capital, LLC
(2)(4)
 Capital Markets  S+700   1.00  11.93  12/29/2020   12/29/2025   9,257   9,083   9,257 
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)
(2)
 Trading Companies & Distributors  S+475   1.00  10.09  12/31/2019   12/31/2025   7,143   7,079   7,143 
Enverus Holdings, Inc. (fka Drilling Info Holdings)
(2)
 IT Services  S+450   —     9.70  1/31/2020   7/30/2025   14,096   13,936   14,096 
Erie Construction
Mid-west,
LLC
(2)
 Building Products  S+475   1.00  10.34  8/5/2021   7/30/2027   11,089   10,949   11,089 
Fertility (ITC) Investment Holdco, LLC
(2)
 Health Care Providers & Services  S+650   1.00  11.63  1/4/2023   1/3/2029   10,330   10,038   10,330 
Foundation Consumer Brands, LLC
(2)
 Personal Products  S+625   1.00  11.47  2/12/2021   2/12/2027   11,876   11,680   11,876 
Glooko, Inc.
(2)
 Health Care Technology  L+790   0.10  13.06  9/30/2021   10/1/2026   2,831   2,850   2,852 
GSM Acquisition Corp.
(2)
 Leisure Equipment & Products  S+500   1.00  10.50  4/20/2021   11/16/2026   13,998   13,904   13,858 
Higginbotham Insurance Agency, Inc.
(2)
 Insurance  S+525   1.00  10.45  11/25/2020   11/25/2026   8,089   8,012   8,089 
High Street Buyer, Inc.
(2)
 Insurance  S+600   0.75  10.79  4/16/2021   4/16/2028   11,886   11,698   11,886 
Human Interest Inc.
(2)
 Internet Software & Services  S+785   1.00  13.01  6/30/2022   7/1/2027   6,799   6,717   6,799 
iCIMS, Inc.
(2)
 Software  S+725   0.75  12.38%
(7)
 
  8/18/2022   8/18/2028   13,974   13,759   13,974 
Kaseya, Inc.
(2)
 Software  S+575   0.75  11.35%
(12)
 
  6/22/2022   6/23/2029   11,006   10,860   11,006 
Kid Distro Holdings, LLC (Distro Kid)
(2)
 Software  S+575   1.00  11.14  9/24/2021   10/1/2027   12,394   12,207   12,394 
KORE Wireless Group, Inc.
(2)
 Wireless Telecommunication Services  S+550   —     10.84  3/12/2019   12/21/2024   14,030   13,945   14,030 
Maurices, Incorporated
(2)
 Specialty Retail  S+675   1.00  9.78  8/27/2021   6/1/2024   5,286   5,265   5,286 
Meditrina, Inc.
(2)
 Health Care Equipment & Supplies  S+550   3.45  10.67  12/20/2022   12/1/2027   1,212   1,208   1,212 
MRI Software LLC
(2)
 Software  S+550   1.00  10.83  7/23/2019   2/10/2026   15,230   15,120   15,230 
Neuronetics, Inc.
(2)
 Health Care Equipment & Supplies  S+565   3.95  10.82  3/2/2020   3/29/2028   3,274   3,272   3,282 
Nexus Intermediate III, LLC (Vortex)
(2)
 Professional Services  L+550   0.75  10.82  12/13/2021   12/6/2027   5,411   5,338   5,411 
Orthopedic Care Partners Management, LLC
(2)
 Health Care Providers & Services  S+650   1.00  11.66  8/17/2022   5/16/2024   5,672   5,646   5,672 
Outset Medical, Inc.
(2)(4)
 Health Care Equipment & Supplies  S+515   2.75  10.32  11/3/2022   11/1/2027   11,865   11,859   11,865 
Pediatric Home Respiratory Services, LLC
(2)
 Health Care Providers & Services  S+625   1.00  11.45  8/19/2022   12/4/2024   2,685   2,653   2,685 
Peter C. Foy & Associates Insurance Services, LLC
(2)
 Insurance  S+600   0.75  11.22  10/29/2021   11/1/2028   15,500   15,375   15,500 
Pinnacle Treatment Centers, Inc.
(2)
 Health Care Providers & Services  S+675   1.00  12.16  1/22/2020   1/2/2026   8,297   8,208   8,297 
Plastics Management, LLC
(2)
 Health Care Providers & Services  S+500   1.00  10.44  8/26/2021   8/18/2027   15,135   14,971   15,135 
RQM+ Corp.
(2)
 Life Sciences Tools & Services  S+575   1.00  11.51  8/20/2021   8/12/2026   15,601   15,443   15,601 
RSC Acquisition, Inc.
(2)
 Insurance  S+550   0.75  10.64  10/5/2020   11/1/2026   18,183   17,962   18,183 
RxSense Holdings LLC
(2)
 Diversified Consumer Services  S+500   1.00  10.15  3/17/2020   3/13/2026   14,562   14,432   14,562 
Description
 
  
Industry

  
Spread above
Index
(3)
   
Floor
 
  
Interest

Rate 
(1)
  
Acquisition

Date
   
Maturity

Date
   
Par

Amount
   
Cost
   
Fair
Value
 
    
                              
Bank Debt/Senior Secured Loans —186.9%
 
         
Accession Risk Management Group, Inc. (f/k/a RSC Acquisition, Inc.)
(2)
  Insurance
   S+550    0.75  11.02  10/5/2020    11/1/2026   $19,553   $19,333   $19,553 
ACRES Commercial Mortgage, LLC
(2)
  Diversified
Financial Services

   S+705    1.00  12.49  12/24/2021    8/21/2028    12,660    12,461    12,660 
Alimera Sciences, Inc.
(2)
  Pharmaceuticals
   S+515    4.60  10.48  12/31/2019    5/1/2028    5,893    5,919    6,066 
All States Ag Parts, LLC
(2)
  Trading
Companies &
Distributors

   S+600    1.00  11.60  9/1/2021    9/1/2026    5,178    5,116    5,178 
Apex Service Partners, LLC
(2)
  Diversified
Consumer Services

   S+525    1.00  10.67  11/5/2021    7/31/2025    20,699    20,478    20,699 
Arcutis Biotherapeutics, Inc.
(2)(4)
  Pharmaceuticals
   S+745    0.10  12.88  12/22/2021    1/1/2027    24,520    24,945    24,950 
Ardelyx, Inc.
(2)(4)
  Pharmaceuticals
   S+795    1.00  13.30  2/23/2022    3/1/2027    3,319    3,356    3,423 
Basic Fun, Inc.
(2)
  Specialty Retail
   S+650    1.00  12.17  10/30/2020    7/2/2024    960    960    960 
BayMark Health Services, Inc.
(2)
  Health Care
Providers &
Services

   S+500    1.00  10.65  6/29/2021    6/11/2027    15,741    15,632    15,741 
BridgeBio Pharma, Inc.
(2)(4)
  Biotechnology
   —     —    9.00%
(6)
 
  11/17/2021    11/17/2026    14,691    14,658    14,728 
CC SAG Holdings Corp. (Spectrum Automotive)
(2)
  Diversified
Consumer Services
    S+575    0.75  11.18  6/29/2021    6/29/2028    12,577    12,416    12,577 
Cerapedics, Inc.
(2)
  Biotechnology
   S+620    2.75  11.53  12/27/2022    1/1/2028    9,698    9,720    9,722 
Enhanced Permanent Capital, LLC
(2)(4)
  Capital Markets
   S+700    1.00  12.26  12/29/2020    12/29/2025    9,062    8,907    9,062 
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)
(2)
  Trading
Companies &
Distributors

   S+475    1.00  10.24  12/31/2019    12/31/2025    7,127    7,068    7,127 
Enverus Holdings, Inc. (fka Drilling Info Holdings)
(2)
  IT Services
   S+450    —    9.92  1/31/2020    7/30/2025    14,053    13,910    14,053 
Erie Construction
Mid-west,
LLC
(2)
  Building Products
   S+475    1.00  10.34  8/5/2021    7/30/2027    10,943    10,813    10,943 
Fertility (ITC) Investment Holdco, LLC
(2)
  Health Care
Providers &
Services

   S+650    1.00  11.63  1/4/2023    1/3/2029    10,304    10,022    10,304 
Foundation Consumer Brands, LLC
(2)
  Personal Products
   S+625    1.00  11.77  2/12/2021    2/12/2027    11,721    11,540    11,721 
Glooko, Inc.
(2)
  Health Care
Technology

   S+790    0.10  13.33  9/30/2021    10/1/2026    2,123    2,145    2,165 
GSM Acquisition Corp.
(2)
  Leisure
Equipment &
Products

   S+500    1.00  10.65  4/20/2021    11/16/2026    13,963    13,875    13,963 
High Street Buyer, Inc.
(2)
  Insurance
   S+600    0.75  11.29  4/16/2021    4/16/2028    12,007    11,824    12,007 
Human Interest Inc.
(2)
  Internet Software &
Services

   S+785    1.00  13.18  6/30/2022    7/1/2027    6,799    6,731    6,799 
iCIMS, Inc.
(2)
  Software
   S+725    0.75  12.63%
(7)
 
  8/18/2022    8/18/2028    14,084    13,877    14,084 
Kaseya, Inc.
(2)
  Software
   S+625    0.75  11.62%
(12)
 
  6/22/2022    6/23/2029    11,030    10,888    11,030 
Kid Distro Holdings, LLC (Distro Kid)
(2)
  Software
   S+550    1.00  11.04  9/24/2021    10/1/2027    12,362    12,185    12,362 
KORE Wireless Group, Inc.
(2)
  Wireless
Telecommunication
Services

   S+550    —    10.99  3/12/2019    12/21/2024    13,993    13,923    13,993 
Maurices, Incorporated
(2)
  Specialty Retail
   S+675    1.00  9.94  8/27/2021    6/1/2024    4,685    4,678    4,685 
Meditrina, Inc.
(2)
  Health Care
Equipment &
Supplies

   S+550    3.45  10.83  12/20/2022    12/1/2027    1,212    1,211    1,218 
MRI Software LLC
(2)
  Software
   S+550    1.00  10.99  7/23/2019    2/10/2026    15,191    15,092    15,191 
Neuronetics, Inc.
(2)
  Health Care
Equipment &
Supplies

   S+565    3.95  10.98  3/2/2020    3/29/2028    3,274    3,280    3,290 
Nexus Intermediate III, LLC (Vortex)
(2)
  Professional
Services

   S+550    0.75  11.36  12/13/2021    12/6/2027    5,396    5,326    5,396 
Oldco AI, LLC (f/k/a AmeriMark)
(2)(5)(11)*
  Internet & Catalog
Retail

   S+800    1.00  —    7/28/2021    10/15/2026    4,271    3,698    —  
Oldco AI, LLC (f/k/a AmeriMark)
(5)(11)
  Internet & Catalog
Retail

   P+475    1.00  13.25  6/16/2023    10/31/2023    282    282    282 
Orthopedic Care Partners Management, LLC
(2)
  Health Care
Providers &
Services

   S+650    1.00  11.96  8/17/2022    5/16/2024    6,385    6,362    6,290 
Outset Medical, Inc.
(2)(4)
  Health Care
Equipment &
Supplies

   S+515    2.75  10.48  11/3/2022    11/1/2027    11,865    11,891    11,894 
Pediatric Home Respiratory Services, LLC
(2)
  Health Care
Providers &
Services

   S+625    1.00  11.67  8/19/2022    12/4/2024    4,235    4,186    4,235 
Peter C. Foy & Associates Insurance Services, LLC
(2)
  Insurance
   S+600    0.75  11.43  10/29/2021    11/1/2028    15,461    15,341    15,152 
Pinnacle Treatment Centers, Inc.
(2)
  Health Care
Providers &
Services

   S+675    1.00  12.32  1/22/2020    1/2/2026    8,275    8,196    8,275 
Plastics Management, LLC
(2)
  Health Care
Providers &
Services

   S+500    1.00  10.44  8/26/2021    8/18/2027    15,096    14,942    15,096 
RQM+ Corp.
(2)
  Life Sciences
Tools & Services

   S+575    1.00  11.40  8/20/2021    8/12/2026    15,561    15,415    15,561 
RxSense Holdings LLC
(2)
  Diversified
Consumer Services

   S+500    1.00  10.47  3/17/2020    3/13/2026    14,524    14,406    14,524 
 
See notes
to
consolidated financial statements.
 
7

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June
September 30, 2023
(in thousands)
 
Description
 
 
Industry
 
Spread above
Index
(3)
  
Floor
 
  
Interest

Rate 
(1)
  
Acquisition
Date
  
Maturity

Date
  
Par Amount
  
Cost
  
Fair
Value
 
Bank Debt/Senior Secured Loans (continued)
         
Southern Orthodontic Partners Management, LLC
(2)
 Health Care Providers & Services  S+600   1.00  11.50  6/3/2022   1/27/2026  $3,791  $3,758  $3,791 
Spectrum Pharmaceuticals, Inc.
(2)
 Biotechnology  S+570   2.30  10.87  9/21/2022   9/1/2027   3,559   3,776   3,835 
SunMed Group Holdings, LLC
(2)
 Health Care Equipment & Supplies  S+575   0.75  11.09  6/16/2021   6/16/2028   7,643   7,542   7,643 
TAUC Management, LLC
(2)
 Health Care Providers & Services  L+525   1.00  10.59  2/12/2021   2/12/2027   9,008   8,918   8,557 
Tilley Distribution, Inc.
(2)
 Trading Companies & Distributors  S+600   1.00  11.39  12/8/2021   12/31/2026   12,557   12,443   12,557 
Transportation Insight, LLC
(2)
 Road & Rail  S+450   1.00  9.64  10/27/2021   12/18/2024   5,581   5,528   5,581 
Ultimate Baked Goods Midco LLC (Rise Baking)
(2)
 Packaged Foods & Meats  S+625   1.00  11.45  8/12/2021   8/13/2027   7,593   7,454   7,593 
Vapotherm, Inc.
(2)
 Health Care Equipment & Supplies  S+930   1.00  14.57%
(8)
 
  2/18/2022   2/1/2027   12,608   12,709   12,766 
Vessco Midco Holdings, LLC
(2)
 Water Utilities  S+450   1.00  9.56  9/3/2021   11/2/2026   3,742   3,711   3,742 
World Insurance Associates, LLC
(2)
 Insurance  S+575   1.00  10.99  10/12/2020   4/1/2026   19,265   18,966   19,265 
               
Total Bank Debt/Senior Secured Loans
   
$
 520,487
 
 
$
 514,531
 
         
                   
Shares/
Units
       
Common Equity/Equity Interests/Warrants — 3.0%
         
Centrexion Therapeutics, Inc. Warrants† Pharmaceuticals     6/28/2019    56,483   27   10 
Meditrina, Inc. Warrants† Health Care Equipment & Supplies     12/20/2022    10,572   8   7 
Senseonics Holdings, Inc. Common Stock†
(4)
 Health Care Equipment & Supplies     7/25/2019    79,501   23   61 
SLR-AMI
Topco Blocker, LLC†
(10)(11)
 Internet & Catalog Retail     6/16/2023    —     6,170   7,826 
Spectrum Pharmaceuticals, Inc. Warrants† Biotechnology     9/21/2022    53,930   17   27 
Vapotherm, Inc.† Health Care Equipment & Supplies     2/18/2022    72,556   93   7 
               
Total Common Equity/Equity Interests/Warrants
 
  
$
6,338
 
 
$
7,938
 
         
Total Investments
(9)
— 195.5%
 
  
$
526,825
 
 
$
522,469
 
Liabilities in Excess of Other Assets — (95.5%)      (255,243
            
Net Assets — 100.0%
     
$
267,226
 
            
Description
 
  
Industry
  
Spread above
Index 
(3)
  
Floor
 
   
Interest

Rate 
(1)
  
Acquisition

Date
   
Maturity

Date
   
Par

Amount
   
Cost
   
Fair
Value
 
                                  
Bank Debt/Senior Secured Loans (continued)
 
                        
Southern Orthodontic Partners Management, LLC
(2)
  Health Care Providers & Services  S+625   1.00   11.89  6/3/2022    1/27/2026   $4,486   $4,450   $4,397 
SunMed Group Holdings, LLC
(2)
  Health Care Equipment & Supplies  S+550   0.75   10.99  6/16/2021    6/16/2028    7,623    7,527    7,623 
TAUC Management, LLC
(2)
  Health Care Providers & Services  L+525   1.00   10.59  2/12/2021    2/12/2027    9,005    8,921    8,375 
Tilley Distribution, Inc.
(2)
  Trading Companies & Distributors  S+600   1.00   11.54  12/8/2021    12/31/2026    12,526    12,419    12,526 
Transportation Insight, LLC
(2)
  Road & Rail  S+450   1.00   9.87  10/27/2021    12/18/2024    5,581    5,536    5,581 
Ultimate Baked Goods Midco LLC (Rise Baking)
(2)
  Packaged Foods & Meats  S+625   1.00   11.67  8/12/2021    8/13/2027    7,574    7,442    7,574 
Vapotherm, Inc.
(2)
  Health Care Equipment & Supplies  S+930   1.00   14.73%
(8)
 
  2/18/2022    2/1/2027    12,901    13,052    13,094 
Vessco Midco Holdings, LLC
(2)
  Water Utilities  S+450   1.00   9.85  9/3/2021    11/2/2026    5,504    5,458    5,504 
World Insurance Associates, LLC
(2)
  Insurance  S+575   1.00   11.14  10/12/2020    4/1/2026    19,217    19,199    19,217 
                                 
 
 
   
 
 
 
Total Bank Debt/Senior Secured Loans
 
  
$
501,012
 
  
$
500,850
 
       
 
 
   
 
 
 
                        
Shares/Units
         
Common Equity/Equity Interests/Warrants — 5.0%
                                        
Assertio Holdings, Inc. Common Stock†
(13)
  Pharmaceuticals               7/31/2023         4,230    17    11 
Centrexion Therapeutics, Inc. Warrants†
  Pharmaceuticals               6/28/2019         56,483    27    10 
Meditrina, Inc. Warrants†
  Health Care Equipment & Supplies               12/20/2022         10,572    8    7 
Senseonics Holdings, Inc. Common Stock†
(4)(13)
  Health Care Equipment & Supplies               7/25/2019         79,501    23    48 
SLR-AMI
Topco Blocker, LLC†
(10)(11)
  Internet & Catalog Retail               6/16/2023         —     17,489    13,283 
Vapotherm, Inc.†
  Health Care Equipment & Supplies               2/18/2022         17,156    103    10 
                                 
 
 
   
 
 
 
Total Common Equity/Equity Interests/Warrants
 
       
$
17,667
 
  
$
13,369
 
         
 
 
   
 
 
 
Total Investments
(9)
— 191.9%
 
       
$
518,679
 
  
$
514,219
 
Liabilities in Excess of Other Assets — (91.9%)
 
   (246,246
                                      
 
 
 
Net Assets — 100.0%
 
  
$
267,973
 
                                      
 
 
 
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME(“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of JuneSeptember 30, 2023.
(2)
Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”)the Company through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
(3)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
(4)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of JuneSeptember 30, 2023, on a fair value basis,
non-qualifying
assets in the portfolio represented 11.9%12.0% of the total assets of the Company.
(5)
AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and AmerimarkAmeriMark Intermediate Holdings, LLC are each
co-Borrowers.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.
(8)
Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.
(9)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $9,108;$9,212; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $6,687$4,423 and $15,795,$13,635, respectively, based on a tax cost of $531,577.$523,431. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as
amended (the “Securities Act”).    These investments are
 generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
See notes to consolidated financial statements.
8

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June 30, 2023
(in thousands)
(10)
Through this entity and other intermediate entities, the Company owns approximately 6.5% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former AmerimarkAmeriMark Interactive, LLC.
(11)
Denotes investments in which we are an “Affiliated Person” but do not exercisingexercise a controlling influence, as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment. Transactions during the period June 16, 2023 (date at which the Company became an Affiliated Person) through JuneSeptember 30, 2023 in these affiliated investments are as follows:
Name of Issuer
  
Fair Value at
June 16,
2023
   
Gross
Additions
   
Gross
Reductions
   
Realized
Gain
(Loss)
   
Change in
Unrealized
Gain
(Loss)
  
Interest/
Dividend
Income
   
Fair Value at
June 30, 2023
 
AmeriMark Intermediate Holdings, LLC  $ 8,243   $ —     $—     $ —     $(3,727 $—     $4,516 
AmeriMark Intermediate Holdings, LLC   —      408    —      —      —     —      408 
SLR-AMI
Topco Blocker, LLC
   6,170    —      —      —      1,656   —      7,826 
                                  
  $ 14,413   $408   $—     $—     $(2,071 $ —     $12,750 
                                  
See notes
to
consolidated financial statements.
 
8

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
September 30, 2023
(in thousands)
Name of Issuer
  
Fair Value at
June 16,
2023
   
Gross
Additions
   
Gross
Reductions
  
Realized Gain
(Loss)
   
Change in Unrealized
Gain (Loss)
  
Fair Value at
September 30,
2023
   
Interest/Dividend
Income
 
Oldco AI, LLC (f/k/a AmeriMark)
  $8,243   $—    $(11,318 $—    $3,075  $—    $—  
Oldco AI, LLC (f/k/a AmeriMark)
   —     1,110    (828  —     —    282    13 
SLR-AMI
Topco Blocker, LLC
   6,170    11,318    —    —     (4,205  13,283    —  
  
 
 
   
 
 
   
 
 
  
 
 
   
 
 
  
 
 
   
 
 
 
  
$
14,413
 
  
$
12,428
 
  
$
(12,146
 
$
— 
 
  
$
(1,130
 
$
13,565
 
  
$
13
 
  
 
 
   
 
 
   
 
 
  
 
 
   
 
 
  
 
 
   
 
 
 
(12)
Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK.
(13)
Denotes a Level 1 investment.
*
Investment is on
non-accrual
status.
st
atus.
Non-income
producing security.
See notes to consolidated financial statements.
 
9

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June
September 30, 2023
(in thousands)
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of

JuneSeptember 30, 2023
 
Insurance14.0
Health Care Providers & Services
   13.414.1
Software
Insurance
   10.112.8
Diversified Consumer Services
Software
   9.210.3
Diversified Consumer Services
9.3
Health Care Equipment & Supplies
   7.07.2
Pharmaceuticals
   6.86.7
Biotechnology5.4
Trading Companies & Distributors
   4.8
Biotechnology
4.8
Life Sciences Tools & Services
   3.0
IT Services
   2.7
Wireless Telecommunication Services
   2.7
Leisure Equipment & Products
2.7
Internet & Catalog Retail
   2.6
Internet & Catalog Retail
Diversified Financial Services
   2.42.5
Diversified Financial Services2.4
Personal Products
   2.3
Building Products
   2.1
Capital Markets
   1.8
Packaged Foods & Meats
   1.5
Internet Software & Services
   1.3
Specialty Retail
1.2
Road & Rail   1.1
Professional Services
Road & Rail
   1.01.1
Water Utilities
   0.71.1
Health Care Technology
Professional Services
   0.51.1
Health Care Technology
0.4
  
 
Total Investments
   100.0
  
 
See notes to consolidated financial statements.
 
10
1
0
SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments
December 31, 2022
(in thousands, except share/unit amounts)
 
Description
 
Industry
 
Spread above
Index
(3)
 
Floor
 
 
Interest
Rate
(1)
 
Acquisition
Date
 
Maturity
Date
 
Par Amount
 
Cost
 
Fair
Value
   
Industry
  
Spread above
Index
(3)
   
Floor
 
 
Interest Rate 
(1)
 
Acquisition

Date
   
Maturity

Date
   
Par

Amount
   
Cost
   
Fair
Value
 
Bank Debt/Senior Secured Loans — 271.5%
         
Bank Debt/Senior Secured Loans — 271.5%
 
         
ACRES Commercial Mortgage, LLC
(2)
 Diversified Financial Services  S+705   1.00  11.38  12/24/2021   8/21/2028  $12,660  $12,437  $12,660   Diversified
Financial Services
   S+705    1.00  11.38  12/24/2021    8/21/2028   $12,660   $12,437   $12,660 
Alimera Sciences, Inc.
(2)
 Pharmaceuticals  L+765   1.78  11.82  12/31/2019   7/1/2024   3,929   4,059   4,145   Pharmaceuticals   L+765    1.78  11.82  12/31/2019    7/1/2024    3,929    4,059    4,145 
All State Ag Parts, LLC
(2)
 Trading Companies & Distributors  S+575   1.00  10.19  9/1/2021   9/1/2026   5,358   5,279   5,358 
All States Ag Parts, LLC
(2)
  Trading
Companies &
Distributors
   S+575    1.00  10.19  9/1/2021    9/1/2026    5,358    5,279    5,358 
AmeriMark Intermediate Holdings, LLC
(2)(5)
 Internet & Catalog Retail  L+800   1.00  14.77  7/28/2021   10/15/2026   21,189   20,858   20,129   Internet & Catalog
Retail
   L+800    1.00  14.77  7/28/2021    10/15/2026    21,189    20,858    20,129 
Apex Service Partners, LLC
(2)
 Diversified Consumer Services  S+525   1.00  9.42  11/5/2021   7/31/2025   21,450   21,134   21,450   Diversified
Consumer Services
   S+525    1.00  9.42  11/5/2021    7/31/2025    21,450    21,134    21,450 
Arcutis Biotherapeutics, Inc.
(2)(4)
 Pharmaceuticals  L+745   0.10  11.62  12/22/2021   1/1/2027   24,520   24,654   24,827   Pharmaceuticals   L+745    0.10  11.62  12/22/2021    1/1/2027    24,520    24,654    24,827 
Ardelyx, Inc.
(2)(4)
 Pharmaceuticals  L+795   0.10  12.12  2/23/2022   3/1/2027   3,319   3,328   3,328   Pharmaceuticals   L+795    0.10  12.12  2/23/2022    3/1/2027    3,319    3,328    3,328 
Basic Fun, Inc.
(2)
 Specialty Retail  L+550   1.00  10.27  10/30/2020   10/30/2023   966   961   966   Specialty Retail   L+550    1.00  10.27  10/30/2020    10/30/2023    966    961    966 
BayMark Health Services, Inc.
(2)
 Health Care Providers & Services  L+500   1.00  9.73  6/29/2021   6/11/2027   15,861   15,733   15,861   Health Care
Providers &
Services
   L+500    1.00  9.73  6/29/2021    6/11/2027    15,861    15,733    15,861 
BridgeBio Pharma, Inc.
(2)(4)
 Biotechnology  —     —     9.00%
(6)
 
  11/17/2021   11/17/2026   14,362   14,257   14,362   Biotechnology   —     —    9.00%
(6)
 
  11/17/2021    11/17/2026    14,362    14,257    14,362 
CC SAG Holdings Corp. (Spectrum Automotive)
(2)
 Diversified Consumer Services  L+575   0.75  10.48  6/29/2021   6/29/2028   6,491   6,407   6,491   Diversified
Consumer Services
   L+575    0.75  10.48  6/29/2021    6/29/2028    6,491    6,407    6,491 
Centrexion Therapeutics, Inc.
 Pharmaceuticals  L+725   2.45  11.42  6/28/2019   1/1/2024   2,314   2,417   2,453   Pharmaceuticals   L+725    2.45  11.42  6/28/2019    1/1/2024    2,314    2,417    2,453 
Cerapedics, Inc.
(2)
 Biotechnology  S+620   2.75  10.52  12/27/2022   1/1/2028   9,698   9,674   9,673   Biotechnology   S+620    2.75  10.52  12/27/2022    1/1/2028    9,698    9,674    9,673 
Enhanced Permanent Capital, LLC
(2)(4)
 Capital Markets  L+700   1.00  10.13  12/29/2020   12/29/2025   7,503   7,352   7,503   Capital Markets   L+700    1.00  10.13  12/29/2020    12/29/2025    7,503    7,352    7,503 
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)
(2)
 Trading Companies & Distributors  S+475   1.00  9.43  12/31/2019   12/31/2025   7,570   7,490   7,570   Trading
Companies &
Distributors
   S+475    1.00  9.43  12/31/2019    12/31/2025    7,570    7,490    7,570 
Enverus Holdings, Inc. (fka Drilling Info Holdings)
(2)
 IT Services L+450 —   8.88 1/31/2020 7/30/2025 14,454 14,252 14,454   IT Services   L+450       8.88  1/31/2020    7/30/2025    14,454    14,252    14,454 
Erie Construction
Mid-west,
LLC
(2)
 Building Products  S+475   1.00  9.79  8/5/2021   7/30/2027   11,381   11,222   11,381   Building Products   S+475    1.00  9.79  8/5/2021    7/30/2027    11,381    11,222    11,381 
Foundation Consumer Brands, LLC
(2)
 Personal Products  L+550   1.00  10.15  2/12/2021   2/12/2027   12,288   12,063   12,288   Personal Products   L+550    1.00  10.15  2/12/2021    2/12/2027    12,288    12,063    12,288 
Glooko, Inc.
(2)
 Health Care Technology  L+790   0.10  12.07  9/30/2021   10/1/2026   2,831   2,838   2,838   Health Care
Technology
   L+790    0.10  12.07  9/30/2021    10/1/2026    2,831    2,838    2,838 
GSM Acquisition Corp.
(2)
 Leisure Equipment & Products  S+500   1.00  9.03  4/20/2021   11/16/2026   14,069   13,961   13,928   Leisure
Equipment &
Products
   S+500    1.00  9.03  4/20/2021    11/16/2026    14,069    13,961    13,928 
Higginbotham Insurance Agency, Inc.
(2)
 Insurance  L+525   0.75  9.63  11/25/2020   11/25/2026   8,130   8,043   8,130   Insurance   L+525    0.75  9.63  11/25/2020    11/25/2026    8,130    8,043    8,130 
High Street Buyer, Inc.
(2)
 Insurance  L+600   0.75  8.75  4/16/2021   4/16/2028   11,606   11,408   11,606   Insurance   L+600    0.75  8.75  4/16/2021    4/16/2028    11,606    11,408    11,606 
Human Interest Inc.
(2)
 Internet Software & Services  S+785   1.00  11.97  6/30/2022   7/1/2027   6,799   6,690   6,799   Internet Software &
Services
   S+785    1.00  11.97  6/30/2022    7/1/2027    6,799    6,690    6,799 
iCIMS, Inc.
(2)
 Software  S+725   0.75  11.52%
(7)
 
  8/18/2022   8/18/2028   13,757   13,527   13,517   Software   S+725    0.75  11.52%
(7)
 
  8/18/2022    8/18/2028    13,757    13,527    13,517 
Ivy Fertility Services, LLC
(2)
 Health Care Providers & Services  L+625   1.00  10.39  12/22/2021   2/25/2026   10,515   10,369   10,620   Health Care
Providers &
Services
   L+625    1.00  10.39  12/22/2021    2/25/2026    10,515    10,369    10,620 
Kaseya, Inc.
(2)
 Software  S+575   0.75  10.33  6/22/2022   6/23/2029   10,966   10,810   10,966   Software   S+575    0.75  10.33  6/22/2022    6/23/2029    10,966    10,810    10,966 
Kid Distro Holdings, LLC (Distro Kid)
(2)
 Software  L+575   1.00  10.48  9/24/2021   10/1/2027   12,457   12,251   12,457   Software   L+575    1.00  10.48  9/24/2021    10/1/2027    12,457    12,251    12,457 
KORE Wireless Group, Inc.
(2)
 Wireless Telecommunication Services  S+550   —     10.08  3/12/2019   12/21/2024   14,104   13,992   14,104   Wireless
Telecommunication
Services
   S+550    —    10.08  3/12/2019    12/21/2024    14,104    13,992    14,104 
Maurices, Incorporated
(2)
 Specialty Retail  S+675   1.00  8.74  8/27/2021   6/1/2024   4,947   4,891   4,947   Specialty Retail   S+675    1.00  8.74  8/27/2021    6/1/2024    4,947    4,891    4,947 
Meditrina, Inc.
(2)
 Health Care Equipment & Supplies  S+550   3.45  9.82  12/20/2022   12/1/2027   1,212   1,201   1,209   Health Care
Equipment &
Supplies
   S+550    3.45  9.82  12/20/2022    12/1/2027    1,212    1,201    1,209 
MRI Software LLC
(2)
 Software  L+550   1.00  10.23  7/23/2019   2/10/2026   15,308   15,180   15,308   Software   L+550    1.00  10.23  7/23/2019    2/10/2026    15,308    15,180    15,308 
NAC Holding Corporation (Jaguar)
(2)
 Insurance  S+525   1.00  9.45  7/30/2021   9/28/2024   12,461   12,355   12,461   Insurance   S+525    1.00  9.45  7/30/2021    9/28/2024    12,461    12,355    12,461 
Neuronetics, Inc.
(2)
 Health Care Equipment & Supplies  L+765   1.66  11.82  3/2/2020   2/28/2025   3,056   3,143   3,224   Health Care
Equipment &
Supplies
   L+765    1.66  11.82  3/2/2020    2/28/2025    3,056    3,143    3,224 
Nexus Intermediate III, LLC (Vortex)
(2)
 Professional Services  L+550   0.75  10.22  12/13/2021   12/6/2027   5,947   5,858   5,947   Professional
Services
   L+550    0.75  10.22  12/13/2021    12/6/2027    5,947    5,858    5,947 
Oral Surgery Partners Holdings, LLC
 Health Care Providers & Services  S+625   1.00  10.92  11/29/2022   5/10/2024   2,206   2,164   2,162   Health Care
Providers &
Services
   S+625    1.00  10.92  11/29/2022    5/10/2024    2,206    2,164    2,162 
Orthopedic Care Partners Management, LLC
(2)
 Health Care Providers & Services  S+650   1.00  10.91  8/17/2022   5/16/2024   4,226   4,200   4,226   Health Care
Providers &
Services
   S+650    1.00  10.91  8/17/2022    5/16/2024    4,226    4,200    4,226 
Outset Medical, Inc.
(2)(4)
 Health Care Equipment & Supplies  S+515   2.75  9.33  11/3/2022   11/1/2027   11,865   11,796   11,775   Health Care
Equipment &
Supplies
   S+515    2.75  9.33  11/3/2022    11/1/2027    11,865    11,796    11,775 
Pediatric Home Respiratory Services, LLC
(2)
 Health Care Providers & Services  S+625   1.00  10.67  8/19/2022   12/4/2024   1,802   1,778   1,784   Health Care
Providers &
Services
   S+625    1.00  10.67  8/19/2022    12/4/2024    1,802    1,778    1,784 
Peter C. Foy & Associates Insurance Services, LLC
(2)
 Insurance  S+600   0.75  11.21  10/29/2021   11/1/2028   15,579   15,444   15,579   Insurance   S+600    0.75  11.21  10/29/2021    11/1/2028    15,579    15,444    15,579 
Pinnacle Treatment Centers, Inc.
(2)
 Health Care Providers & Services  S+650   1.00  10.57  1/22/2020   1/2/2026   8,339   8,233   8,152   Health Care
Providers &
Services
   S+650    1.00  10.57  1/22/2020    1/2/2026    8,339    8,233    8,152 
Plastics Management, LLC
(2)
 Health Care Providers & Services  S+500   1.00  9.89  8/26/2021   8/18/2027   12,117   11,967   12,117   Health Care
Providers &
Services
   S+500    1.00  9.89  8/26/2021    8/18/2027    12,117    11,967    12,117 
Revlon Consumer Products Corporation
(2)
 Personal Products  P+475   2.75  12.25  5/7/2021   6/17/2023   13,905   13,876   13,974   Personal Products   P+475    2.75  12.25  5/7/2021    6/17/2023    13,905    13,876    13,974 
RQM+ Corp.
(2)
 Life Sciences Tools & Services  S+575   1.00  10.59  8/20/2021   8/12/2026   15,680   15,499   15,680   Life Sciences
Tools & Services
   S+575    1.00  10.59  8/20/2021    8/12/2026    15,680    15,499    15,680 
RSC Acquisition, Inc.
(2)
 Insurance  S+550   0.75  9.26  10/5/2020   11/1/2026   9,345   9,191   9,345   Insurance   S+550    0.75  9.26  10/5/2020    11/1/2026    9,345    9,191    9,345 
RxSense Holdings LLC
(2)
 Diversified Consumer Services  L+500   1.00  9.41  3/17/2020   3/13/2026   14,674   14,522   14,674   Diversified
Consumer Services
   L+500    1.00  9.41  3/17/2020    3/13/2026    14,674    14,522    14,674 
See notes to consolidated financial statements.
 
1
111

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2022
(in thousands)
 
Description
 
Industry
 
Spread above
Index
(3)
 
Floor
 
 
Interest
Rate
(1)
 
Acquisition
Date
 
Maturity
Date
 
Par Amount
 
Cost
 
Fair
Value
   
Industry
  
Spread above
Index 
(3)
  
Floor
 
   
Interest
Rate
(1)
 
Acquisition
Date
   
Maturity
Date
   
Par

Amount
   
Cost
   
Fair
Value
 
                                
Bank Debt/Senior Secured Loans (continued)
                          
Southern Orthodontic Partners Management, LLC
(2)
 Health Care Providers & Services  S+600   1.00  10.84  6/3/2022   1/27/2026  $1,901  $1,884  $1,901   
Health Care Providers & Services
  S+600   1.00   10.84 6/3/2022    1/27/2026   $1,901   $1,884   $1,901 
Spectrum Pharmaceuticals, Inc.
(2)
 Biotechnology  S+570   2.30  9.88  9/21/2022   9/1/2027   3,559   3,519   3,524   
Biotechnology
  S+570   2.30   9.88 9/21/2022    9/1/2027    3,559    3,519    3,524 
SunMed Group Holdings, LLC
(2)
 Health Care Equipment & Supplies  L+575   0.75  10.48  6/16/2021   6/16/2028   7,929   7,815   7,929   
Health Care Equipment & Supplies
  L+575   0.75   10.48 6/16/2021    6/16/2028    7,929    7,815    7,929 
TAUC Management, LLC
(2)
 Health Care Providers & Services  L+525   1.00  9.98  2/12/2021   2/12/2027   9,013   8,912   8,968   
Health Care Providers & Services
  L+525   1.00   9.98 2/12/2021    2/12/2027    9,013    8,912    8,968 
Tilley Distribution, Inc.
(2)
 Trading Companies & Distributors  S+550   1.00  10.14  12/8/2021   12/31/2026   12,762   12,633   12,762   
Trading Companies & Distributors
  S+550   1.00   10.14 12/8/2021    12/31/2026    12,762    12,633    12,762 
Transportation Insight, LLC
(2)
 Road & Rail  L+450   1.00  8.91  10/27/2021   12/18/2024   4,198   4,150   4,198   
Road & Rail
  L+450   1.00   8.91 10/27/2021    12/18/2024    4,198    4,150    4,198 
Ultimate Baked Goods Midco LLC (Rise Baking)
(2)
 Packaged Foods & Meats  L+650   1.00  10.88  8/12/2021   8/13/2027   7,877   7,717   7,877   
Packaged Foods & Meats
  L+650   1.00   10.88 8/12/2021    8/13/2027    7,877    7,717    7,877 
Vapotherm, Inc.
(2)
 Health Care Equipment & Supplies  S+830   1.00  12.58%
(8)
 
  2/18/2022   2/1/2027   12,070   12,076   12,131   
Health Care Equipment & Supplies
  S+830   1.00   12.58%
(8)
 
 2/18/2022    2/1/2027    12,070    12,076    12,131 
Vessco Midco Holdings, LLC
(2)
 Water Utilities  L+450   1.00  7.87  9/3/2021   11/2/2026   2,207   2,189   2,206   
Water Utilities
  L+450   1.00   7.87 9/3/2021    11/2/2026    2,207    2,189    2,206 
World Insurance Associates, LLC
(2)
 Insurance  S+575   1.00  10.07  10/12/2020   4/1/2026   19,614   19,261   18,829   
Insurance
  S+575   1.00   10.07 10/12/2020    4/1/2026    19,614    19,261    18,829 
        
 
  
 
     
 
   
 
 
Total Bank Debt/Senior Secured Loans
Total Bank Debt/Senior Secured Loans
   
$
528,920
 
 
$
532,753
 
    
$
528,920
 
  
$
532,753
 
  
 
  
 
     
 
   
 
 
                      
Shares/Units
         
           
Shares/
Units
     
Common Equity/Equity Interests/Warrants — 0.0%
                          
Centrexion Therapeutics, Inc. Warrants†
 Pharmaceuticals     6/28/2019    56,483   27   16   
Pharmaceuticals
       6/28/2019      56,483    27    16 
Meditrina, Inc. Warrants†
 Health Care Equipment & Supplies     12/20/2022    10,572   8   8   
Health Care Equipment & Supplies
       12/20/2022      10,572    8    8 
Senseonics Holdings, Inc. Common Stock†
(4)
 Health Care Equipment & Supplies     7/25/2019    79,501   23   82   
Health Care Equipment & Supplies
       7/25/2019      79,501    23    82 
Spectrum Pharmaceuticals, Inc. Warrants†
 Biotechnology     9/21/2022    53,930   17   5   
Biotechnology
       9/21/2022      53,930    17    5 
Vapotherm, Inc.†
 Health Care Equipment & Supplies     2/18/2022    12,960   75   31   
Health Care Equipment & Supplies
       2/18/2022      12,960    75    31 
        
 
  
 
                
 
   
 
 
Total Common Equity/Equity Interests/Warrants
Total Common Equity/Equity Interests/Warrants
 
  
$
150
 
 
$
142
 
Total Common Equity/Equity Interests/Warrants
 
    
$
150
 
  
$
142
 
  
 
  
 
     
 
   
 
 
Total Investments
(9)
— 271.5%
Total Investments
(9)
— 271.5%
 
  
$
 529,070
 
 
$
 532,895
 
Total Investments
(9)
— 271.5%
 
    
$
529,070
 
  
$
532,895
 
Liabilities in Excess of Other Assets — (171.5%)
 
     (336,641
Liabilities in Excess of Other Assets —(171.5%)Liabilities in Excess of Other Assets —(171.5%)              (336,641  
         
 
                
 
   
Net Assets — 100.0%
Net Assets — 100.0%
     
$
196,254
                
$
196,254
 
  
         
 
                
 
   
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME(“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2022.
(2)
Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”)the Company through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
(3)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
(4)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis,
non-qualifying
assets in the portfolio represented
11.2
% 11.2% of the total assets of the Company.
(5)
AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each
co-Borrowers.
Amerimark may elect to defer up to 8.00% of the coupon as PIK.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.
(8)
Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.
(9)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $927; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $5,202 and $6,129, respectively, based on a tax cost of $533,822. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
Non-income
producing security.
See notes to consolidated financial statements.
 
12

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2022
(in thousands)
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of

December 31, 2022
 
Insurance
   14.3
Health Care Providers & Services
   12.4
Software
   9.8
Diversified Consumer Services
   8.0
Health Care Equipment & Supplies
   6.8
Pharmaceuticals
   6.5
Biotechnology
   5.2
Personal Products
   4.9
Trading Companies & Distributors
   4.8
Internet & Catalog Retail
   3.8
Life Sciences Tools & Services
   2.9
IT Services
   2.7
Wireless Telecommunication Services
   2.7
Leisure Equipment & Products
   2.6
Diversified Financial Services
   2.4
Building Products
   2.1
Packaged Foods & Meats
   1.5
Capital Markets
   1.4
Internet Software & Services
   1.3
Professional Services
   1.1
Specialty Retail
   1.1
Road & Rail
   0.8
Health Care Technology
   0.5
Water Utilities
   0.4
  
 
Total Investments
   100.0
  
 
See notes to consolidated financial statements.
 
13

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited)
June
September 30, 2023
(in thousands, except unit amounts)
Note 1. Organization
SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on
May 18, 2018
.2018. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”).
On October 5, 2018 (the “Initial Closing Date”), the Company closed on $326,000 in capital commitments. On March 12, 2019, the sale and issuance of 2,800,000 of the Company’s units (“Units”), at an aggregate purchase price of $28,000 ($10.00 per unit)Unit) occurred and the Company commenced operations. As of JuneSeptember 30, 2023, $261,500 of capital commitments were drawn and $64,500 were unfunded.
The Company has implemented a corporate lending strategy focused on sourcing, underwriting and managing a diverse portfolio of private senior secured loans primarily to upper middle market companies (generally,
aggregate
loan sizes of $100,000 to $300,000 to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25,000 and $100,000) across the United States. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in
non-traditional
asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features and/or other types of unfunded commitments.
The offering period of the Company ended on April 5, 2019 (the “Offering Period”). The investment period of the Company ended on December 31, 2022. The term of the Company will be six years from the end of the Offering Period unless the Company is liquidated earlier as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the boardCompany’s Board of directorsDirectors (the “Board”) for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a
non-1940
Act vote as described in the LLC Agreement. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.
Note 2. Summary of Significant Accounting Policies
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform
to
current period presentation.
 
14

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form
10-Q
and Regulation
S-X,
as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported periods.period. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2023.
In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of financial statements, have been included.
The significant accounting policies consistently followed by the Company are:
 
 (a)
Investment transactions are accounted for on the trade date;
 (b)
In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows:
 (i)
securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation;
 (ii)
exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes;
 (iii)
short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and
 (iv)
securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below:
 a.
the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment;
 b.
preliminary valuation conclusions are then documented and discussed with senior management of the Adviser;
 c.
the audit committee of the Board of Directors ( the “Board”) reviews the preliminary valuations of the Adviser and third partythird-party valuation specialist, if any, and responds to the valuation recommendations
to
reflect any comments; and
15

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
 d.
the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third partythird-party valuation specialist, if any, which may from time to time be engaged by the Board.
The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion.
The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC
820-10,
certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the sixnine months ended JuneSeptember 30, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process.
ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:
Level
 1
: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.
Level
 2
: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.
Level
 3
: Unobservable inputs for the asset or liability.
In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.
 
 (c)
Gains or losses on investments are calculated by using the specific identification method.
16
SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
 (d)
The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other
non-recurring
fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned.
 (e)
The Company intends to comply with the applicable provisions of the Code pertaining to
RICs
to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.
 (f)
Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP.
 (g)
Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.
 (h)
In accordance with Regulation
S-X
and ASC Topic 810—
Consolidation
, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.
 (i)
The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.
 (j)
In accordance with ASC
835-30,
the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.
 (k)
The T
he
Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units,Units, in accordance with ASC
946-20-25.
17

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
 (l)
Investments that are expected to pay regularly scheduled interest in cash are generally placed on
non-accrual
status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such
non-accrual
investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment.
 (m)
The Company records expenses directly related to its organization as incurred.
 (n)
The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.
Note 3. Agreements and Related Party Transactions
The Company has entered into an investment management agreement with the Adviser (the “Investment Management Agreement”) pursuant to which it will pay management fees, administrative coordinator fees and incentive fees to the Adviser. The Company will pay the Adviser a fee for investment advisory and management services consisting of two components: a base management fee and an incentive fee. The Company will also pay the Adviser (in its capacity as Administrative Coordinator, defined herein) an administration fee for administrative and coordination services. The cost of the base management fee, the incentive fee, and the administration fee will be borne by the Unitholders.
Management Fees and Administration Fees
The Company will pay the Adviser a management fee (the “Management Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (each such date, the “Management Fee Calculation Date”), in an amount equal to 1.5% per annum of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company plus (ii) the total amount of credit drawn on subscription credit facilities), and payable quarterly in arrears after such Management Fee Calculation Date.
Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay the Administrative Coordinator, a fee (the “Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as the aggregate accreted and amortized cost of all
Portfolio Investments,
, including any amounts reinvested in investments and the cost of investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third partythird-party services needed or required by the Company and (iii) certain Unitholder servicing functions.
 
18

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Each of the Management Fee and the Administration Fee will be appropriately adjusted for any stub period. Such fees will be paid out of net current income and/or disposition proceeds or, to the extent such amounts are not available, from unfunded capital commitments that will be drawn down, or borrowings of the Company. In the event that the Adviser arranges for the Company to pay any portion of a placement fee to a placement agent, the amount of
Management Fees
otherwise payable shall be reduced by an amount equal to 100% of such payment to the placement agent.
Incentive Fee
The Company will make distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, warrant gains, prepayment fees and exit fees, other than Disposition Proceeds. The Adviser will apportion each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. Amounts of Investment Proceeds apportioned to Unitholders will be divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee,
, on the other hand, in the following amounts and order of priority:
(A)
Return of Capital Contributions
. First, 100% to such Unitholder until such Unitholder has received cumulative distributions of Investment Proceeds pursuant to this clause (i)(A) equal to such Unitholder’s total Capital Contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses (as defined below) and other Company expenses);
(B)
Unitholder Preferred Return
. Second, 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and pursuant to clause (ii)(A) and clause (ii)(C) below equal to 6% per annum, compounded annually, on such Unitholder’s unreturned capital contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses and other Company expenses) (the
Preferred“Preferred Return”);
(C)
Adviser Catch Up to 15%
. Third, 80% of all remaining Disposition Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to
t
o Unitholders pursuant to this clause (C) and clause (ii)(B) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (B) above and this clause (C) and pursuant to clause (ii)(A) and clause (ii)(B); and
 
19

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
(D)
85%/15%
 Shares
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee,
, on the other hand, in the following amounts and order of priority:
(A)
Unitholder Preferred Return
. First, 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) equal to the Preferred Return;
(B)
Adviser Catch Up to 15%
. Second, 80% of all remaining Current Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (A) above and this clause (B) and pursuant to Section clause (i)(B) and clause (i)(C); and
(C)
85%/15% Units
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
The Adviser has the right with respect to all Unitholders, upon approval of the Company’s independent directors, to waive or reduce the incentive fee to which it is entitled. The Adviser may also elect not to receive all or any portion of the incentive fee that would otherwise be distributed to it, and may cause any or all amounts subsequently available for distribution to the Unitholders to be distributed to the Adviser until it has received the same aggregate amount of incentive fees had it not previously waived receipt of incentive fees.
The Adviser will be entitled to withhold from any distributions, in its discretion, any required tax withholdings. Amounts of taxes paid or withheld from amounts otherwise distributable to a Unitholder will be deemed distributed for purposes of the calculations above.
Upon liquidation of the Company, the Adviser will be required to restore funds to the Company for distribution to the Unitholders if and to the extent that the Adviser has received cumulative incentive fees in excess of the incentive fees that would have been payable to the Adviser on an aggregate basis covering all transactions of the Company; provided, however, that in no event will the Adviser be required to contribute an aggregate amount in excess of 100% of the net amount distributed to the Adviser (net of taxes) on account of its incentive fees. In addition, the Adviser will apply an interim incentive fee adjustment at the end of each fiscal year so that, in the event of any over-distribution of incentive fee to the Adviser (measured with respect to each Unitholder using the fair value of the Company’s portfolio at the end of the applicable fiscal year as if the Company were to liquidate on such date), future distributions that would, absent such interim incentive fee adjustment, otherwise be distributed to the Adviser as an incentive fee, shall be distributed to such Unitholder until such over-distribution (net of taxes payable by the Adviser with respect to such incentive fee) has been eliminated.
For the three and sixnine months ended JuneSeptember 30, 2023, the Company incurred $1,078$1,102 and $2,136,$3,238, respectively, in Management Fees, $105 and $210,$315, respectively, in Administration Fees and $1,582$1,285 and $1,054,$2,339, respectively, in
incentive fees
.fees. For the three and sixnine months ended JuneSeptember 30, 2022, the Company incurred $889$1,010 and $1,760,$2,770, respectively, in Management Fees, $93$102 and $181,$283, respectively, in Administration Fees and $736$958 and $1,586,$2,544, respectively, in
incentive fees. Incentive Fees.
 
20

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
The aggregate amount of certain operating expenses relating to Unitholders investing directly in the Company will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400,000 in capital commitments, an amount equal to the sum of (x) the product of the capital commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in capital commitments, $2,250. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder.
The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (“Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. $308 of offering expenses were charged to capital and $84 of organizational costs were expensed in 2019.
Note 4. Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:
Level
 1.
 Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.
Level
 2.
 Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 a)
Quoted prices for similar assets or liabilities in active markets;
 b)
Quoted prices for identical or similar assets or liabilities in
non-active
markets;
 c)
Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
 d)
Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
Level
 3.
Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use
in
pricing the asset or liability.
When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).
 
21

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).
A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.
The following tables present the balances of assets measured at fair value on a recurring basis, as of JuneSeptember 30, 2023 and December 31, 2022:
Fair Value Measurements
As of JuneSeptember 30, 2023
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
        
Bank Debt/Senior Secured Loans  $—    $—    $514,531   $514,531 
Common Equity/Equity Interests/Warrants   61    —      7,877    7,938 
                    
Total Investments  $61  $—     $522,408   $522,469 
                    
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                    
Bank Debt/Senior Secured Loans
  $—    $—    $500,850   $500,850 
Common Equity/Equity Interests/Warrants
   59    —     13,310    13,369 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Investments
  $59   $—    $514,160   $514,219 
   
 
 
   
 
 
   
 
 
   
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at JuneSeptember 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500$223,800 and $26,800,$30,000, respectively.
Fair Value Measurements
As of December 31, 2022
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                    
Bank Debt/Senior Secured Loans
  $—    $—    $532,753   $532,753 
Common Equity/Equity Interests/Warrants
   82    —     60    142 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Investments
  $82   $—    $532,813   $532,895 
   
 
 
   
 
 
   
 
 
   
 
 
 
22

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 
31,
2022, the fair value of the SPV Facility and the Subscription Facility would be $267,726 and $70,400, respectively.
The following table provides a summary of the changes in fair value of Level 3 assets for the three and sixnine months ended JuneSeptember 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at JuneSeptember 30, 2023:
 
   
Bank Debt/Senior
Secured Loans
   
Common Equity/Equity
Interests/Warrants
   
Total
 
Fair value, March 31, 2023
  $524,025   $44   $524,069 
Total gains or losses included in earnings:      
Net realized gain   6    —      6 
Net change in unrealized gain   635    1,652    2,287 
Purchase of investment securities   31,071    6,181    37,252 
Proceeds from dispositions of investment securities   (41,206   —      (41,206
Transfers into Level 3   —      —      —   
Transfers out of Level 3   —      —      —   
               
Fair value, June 30, 2023
  $514,531   $7,877   $522,408 
               
Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:      
Net change in unrealized gain  $731   $1,652   $2,383 
               
   
Bank Debt/Senior
Secured Loans
   
Common Equity/Equity
Interests/Warrants
   
Total
 
Fair value, December 31, 2022
  $532,753   $60   $532,813 
Total gains or losses included in earnings:      
Net realized gain   6    —      6 
Net change in unrealized gain (loss)   (9,788   1,629    (8,159
Purchase of investment securities   60,089    6,188    66,277 
Proceeds from dispositions of investment securities   (68,529   —      (68,529
Transfers into Level 3   —      —      —   
Transfers out of Level 3   —      —      —   
               
Fair value, June 30, 2023
  $514,531   $7,877   $522,408 
               
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:      
Net change in unrealized gain (loss)  $(9,563  $1,629   $(7,934
               
   
Bank Debt/Senior
Secured Loans
   
Common Equity/Equity
Interests/Warrants
   
Total
 
Fair value, June 30, 2023
  $514,531   $7,877   $522,408 
Total gains or losses included in earnings:
               
Net realized gain
   —     —     —  
Net change in unrealized gain (loss)
   5,793    (5,879   (86
Purchase of investment securities*   9,334    11,329    20,663 
Proceeds from dispositions of investment securities
   (28,808   (17   (28,825
Transfers into Level 3
   —     —     —  
Transfers out of Level 3
   —     —     —  
   
 
 
   
 
 
   
 
 
 
Fair value, September 30, 2023
  $500,850   $13,310   $514,160 
   
 
 
   
 
 
   
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
               
Net change in unrealized gain (loss)
  $5,959   $(5,869  $90 
   
 
 
   
 
 
   
 
 
 
    
   
Bank Debt/Senior
Secured Loans
   
Common Equity/Equity
Interests/Warrants
   
Total
 
Fair value, December 31, 2022
  $532,753   $60   $532,813 
Total gains or losses included in earnings:
               
Net realized gain
   6    —     6 
Net change in unrealized loss
   (3,995   (4,250   (8,245
Purchase of investment securities*   69,424    17,517    86,941 
Proceeds from dispositions of investment securities
   (97,338   (17   (97,355
Transfers into Level 3
   —     —     —  
Transfers out of Level 3
   —     —     —  
   
 
 
   
 
 
   
 
 
 
Fair value, September 30, 2023
  $500,850   $13,310   $514,160 
   
 
 
   
 
 
   
 
 
 
Unrealized losses for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
               
Net change in unrealized loss
  $(3,643  $(4,262  $(7,905
   
 
 
   
 
 
   
 
 
 
 
*
Includes PIK capitalization and accretion of discount
23

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022:
 
   
Bank Debt/Senior
Secured Loans
   
Common Equity/Equity
Interests/Warrants
   
Total
 
Fair value, December 31, 2021
  $439,661   $13   $439,674 
Total gains or losses included in earnings:
      
Net realized gain (loss)
   —     —     —  
Net change in unrealized gain (loss)
   340    (53   287 
Purchase of investment securities
   188,107    100    188,207 
Proceeds from dispositions of investment securities
   (95,355   —     (95,355
Transfers into Level 3
   —     —     —  
Transfers out of Level 3
   —     —     —  
  
 
 
   
 
 
   
 
 
 
Fair value, December 31, 2022
  $532,753   $60   $532,813 
  
 
 
   
 
 
   
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
      
Net change in unrealized gain (loss)
  $744   $(53  $691 
  
 
 
   
 
 
   
 
 
 
Quantitative Information about Level 3 Fair Value Measurements
The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.
Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities.
 
24
SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Quantitative information about the Company’s Level 3 asset fair value measurements as of JuneSeptember 30, 2023 is summarized in the table below:
 
   
Asset or
Liability
  
Fair Value at
June 30, 2023
   
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans  Asset  $510,015   Income Approach  Market Yield  9.9% – 20.8% (12.0%)
    $4,516   Recovery Analysis  Recoverable Amount  N/A
Common Equity/Equity Interests/Warrants  Asset  $51   Market Approach  Volatility  17.3% - 17.3% (17.3%)
    $7,826   EBITDA Multiple  Comparable Multiple  
6.25x-7.25x (6.75x)
   
Asset or
Liability
   
Fair Value at
September 30,
2023
   
Principal Valuation
Technique/
Methodology
  
Unobservable Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset   $500,850   Income Approach  Market Yield  10.1% - 16.8% (12.1%)
Common Equity/Equity Interests/Warrants
   Asset   $27   Market Approach  Volatility  17.8% - 17.8% (17.8%)
    $13,283   EBITDA Multiple  Comparable Multiple  
6.25x-7.25x
(6.75x)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
   
Asset or
Liability
  
Fair Value at
December 31, 2022
   
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans  Asset  $532,753   Income Approach  Market Yield  9.4% – 16.2% (11.4%)
Common Equity/Equity Interests/Warrants  Asset  $60   Market Approach  Volatility  26.0% - 26.0% (26.0%)
   
Asset or
Liability
   
Fair Value at
December 31,
2022
   
Principal Valuation
Technique/
Methodology
   
Unobservable Input
   
Range (Weighted
Average)
Senior Secured Loans
   Asset   $532,753    Income Approach    Market Yield   9.4% - 16.2% (11.4%)
Common Equity/Equity Interests/Warrants
   Asset   $60    Market Approach    Volatility   26.0% - 26.0% (26.0%)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
inve
stments.
 
25

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Note 5. Debt
SPV Facility
—During the first quarter of 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into the $100,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400,000. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75,000.$75,000
.    On February
 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100,000. On July 16, 2021, the Company entered into an amended SPV Facility, which increased commitments to $125,000, and on August 18, 2021 entered into a second amended SPV Facility which increased commitments to $200,000 and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275,000. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300,000 and changed the interest rate to a SOFR-based calculation. There were $236,500$223,800 of borrowings outstanding as of JuneSeptember 30, 2023 under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted.
Subscription Facility
—During the first quarter of 2019, the Company established the $35,000 Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35,000 to $50,000. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50,000 to $75,000 and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100,000 and the maturity date was extended. On December 28, 2022, the Company entered into the first amendment to the amended and restated loan and security agreement, extending the maturity date to December 31, 2023, reducing commitments to $75,000 and the stated interest rate is SOFR plus 2.80%. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. There were $26,800$30,000 of borrowings outstanding as of JuneSeptember 30, 2023 under the Subscription Facility.
The average annualized interest cost for borrowings for the sixnine months ended JuneSeptember 30, 2023 and the year ended December 31, 2022 was 7.93%8.03% and 4.67%, respectively. These costs are exclusive of other credit facility expenses such as unused fees and fees paid to the
back-up
servicer, if any. The maximum amount borrowed on the credit facilities during the sixnine months ended JuneSeptember 30, 2023 and the year ended December 31, 2022 was $338,126 and $343,350, respectively.
 
26

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Note 6. Commitments and Contingencies
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The
Th
e total amount of these unfunded commitments as of JuneSeptember 30, 2023 and December 31, 2022 is $59,616$47,908 and $98,214, respectively, comprised of the following:
 
   
June 30,
2023
   
December 31,
2022
 
Outset Medical, Inc.  $11,865   $11,865 
Human Interest Inc.   6,799    6,799 
Vessco Midco Holdings, LLC   3,417    4,969 
Glooko, Inc.   3,185    3,185 
Arcutis Biotherapeutics, Inc.   3,065    3,065 
Ardelyx, Inc.   2,716    2,716 
iCIMS, Inc.   2,665    3,867 
Cerapedics, Inc.   2,424    2,424 
High Street Buyer, Inc.   2,040    2,797 
RxSense Holdings, LLC   1,558    1,558 
Pediatric Home Respiratory Services, LLC   1,557    2,451 
Enverus Holdings, Inc.   1,537    1,251 
Maurices, Incorporated   1,491    2,733 
RSC Acquisition, Inc.   1,419    10,328 
Nexus Intermediate III, LLC (Vortex)   1,264    1,264 
Meditrina, Inc.   1,212    1,212 
Spectrum Pharmaceuticals, Inc.   1,186    2,966 
Kid Distro Holdings, LLC   1,121    1,121 
GSM Acquisition Corp.   1,101    1,101 
Foundation Consumer Brands, LLC   967    967 
Basic Fun, Inc.   960    1,195 
Ultimate Baked Goods Midco LLC   750    578 
Orthopedic Care Partners Management, LLC   729    2,200 
Southern Orthodontic Partners Management, LLC   705    2,605 
Kaseya, Inc.   625    1,315 
MRI Software LLC   577    577 
ENS Holdings III Corp. & ES Opco USA LLC   574    179 
SunMed Group Holdings, LLC   515    268 
Transportation Insight, LLC   454    1,860 
World Insurance Associates, LLC   385    135 
TAUC Management, LLC   385    385 
Amerimark Intermediate Holdings, LLC   194    —   
CC SAG Holdings Corp. (Spectrum Automotive)   174    6,568 
Oral Surgery Partners Holdings, LLC   —      3,277 
Plastics Management, LLC   —      3,095 
Erie Construction
Mid-west,
LLC
   —      1,593 
Tilley Chemical Buyer, Inc.   —      670 
Peter C. Foy & Associates Insurance Services, LLC   —      570 
Pinnacle Treatment Centers, Inc.   —      520 
Ivy Fertility Services, LLC   —      499 
BayMark Health Services, Inc.   —      499 
NAC Holdings Corporation   —      470 
Apex Service Partners, LLC   —      345 
All States Ag Parts, LLC   —      172 
          
Total Commitments  $59,616   $98,214 
          
   
September 30,
2023
   
December 31,
2022
 
Outset Medical, Inc.
  $11,865   $11,865 
Human Interest Inc.
   6,799    6,799 
Arcutis Biotherapeutics, Inc.
   3,065    3,065 
Ardelyx, Inc.
   2,716    2,716 
iCIMS, Inc.
   2,555    3,867 
Cerapedics, Inc.
   2,424    2,424 
Neuronetics, Inc.
   1,964    —  
High Street Buyer, Inc.
   1,890    2,797 
Maurices, Incorporated
   1,640    2,733 
RxSense Holdings, LLC
   1,558    1,558 
Enverus Holdings, Inc.
   1,545    1,251 
Nexus Intermediate III, LLC (Vortex)
   1,264    1,264 
Kid Distro Holdings, LLC
   1,121    1,121 
GSM Acquisition Corp.
   1,101    1,101 
Foundation Consumer Brands, LLC
   967    967 
Basic Fun, Inc.
   960    1,195 
Ultimate Baked Goods Midco LLC
   753    578 
Kaseya, Inc.
   625    1,315 
MRI Software LLC.
   577    577 
ENS Holdings III Corp. & ES Opco USA LLC
   574    179 
SunMed Group Holdings, LLC
   515    268 
Transportation Insight, LLC
   454    1,860 
Vessco Midco Holdings, LLC
   417    4,969 
TAUC Management, LLC
   385    385 
CC SAG Holdings Corp. (Spectrum Automotive)
   174    6,568 
Accession Risk Management Group, Inc.
   —     10,328 
Oral Surgery Partners Holdings, LLC
   —     3,277 
Glooko, Inc.
   —     3,185 
Plastics Management, LLC
   —     3,095 
Spectrum Pharmaceuticals, Inc.
   —     2,966 
Southern Orthodontic Partners Management, LLC
   —     2,605 
Pediatric Home Respiratory Services, LLC
   —     2,451 
Orthopedic Care Partners Management, LLC
   —     2,200 
Erie Construction
Mid-west,
LLC
   —     1,593 
Meditrina, Inc.
   —     1,212 
Tilley Chemical Buyer, Inc.
   —     670 
Peter C. Foy & Associates Insurance Services, LLC
   —     570 
Pinnacle Treatment Centers, Inc.
   —     520 
Ivy Fertility Services, LLC
   —     499 
BayMark Health Services, Inc.
   —     499 
NAC Holdings Corporation
   —     470 
Apex Service Partners, LLC
   —     345 
All States Ag Parts, LLC
   —     172 
World Insurance Associates, LLC
   —     135 
   
 
 
   
 
 
 
Total Commitments
  $47,908   $98,214 
   
 
 
   
 
 
 
 
27

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of JuneSeptember 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
In the normal course of itsour business, we invest or trade in various financial instruments and may enter into various investment activities with
off-balance
sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of
off-balance
sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities.
Note 7. Unitholders’ Capital
Transactions in Unitholders’ capital were as follows:
 
   
Three months
ended
June 30, 2023
   
Three months
ended
June 30, 2022
 
Units at beginning of period   25,190,253    17,137,275 
Units issued   —      1,855,288 
          
Units issued and outstanding at end of period   25,190,253    18,992,563 
          
   
Three months
ended
September 30,
2023
   
Three months
ended
September 30,
2022
 
Units at beginning of period
   25,190,253    18,992,563 
Units issued
   —     —  
  
 
 
   
 
 
 
Units issued and outstanding at end of period
   25,190,253    18,992,563 
  
 
 
   
 
 
 
 
   
Six months
ended
June 30, 2023
   
Six months
ended
June 30, 2022
 
Units at beginning of period   18,992,563    17,137,275 
Units issued   6,197,690    1,855,288 
          
Units issued and outstanding at end of period   25,190,253    18,992,563 
          
   
Nine months
ended
September 30,
2023
   
Nine months
ended
September 30,
2022
 
Units at beginning of period
   18,992,563    17,137,275 
Units issued
   6,197,690    1,855,288 
  
 
 
   
 
 
 
Units issued and outstanding at end of period
   25,190,253    18,992,563 
  
 
 
   
 
 
 
 
28

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Note 8. Financial Highlights
The following is a schedule of financial highlights for the sixnine months ended JuneSeptember 30, 2023 and JuneSeptember 30, 2022:
 
   
Six months ended
June 30, 2023
  
Six months ended
June 30, 2022
 
Per Share Data: (a)   
Net asset value per unit, beginning of period  $10.33  $10.28 
         
Net investment income   0.60   0.49 
Net realized and unrealized gain (loss)   (0.32)*   0.03 
         
Net increase in Unitholders’ capital resulting from operations   0.28   0.52 
Distributions to Unitholders:   
From distributable earnings   —     —   
         
Net asset value per unit, end of period  $10.61  $10.80 
         
Total Return (b)(c)   2.71  5.06
Unitholders’ capital, end of period  $267,226  $205,103 
Units outstanding, end of period   25,190,253   18,992,563 
         
Ratios to average net assets of Unitholders’ Capital (c):   
Net investment income   5.82  4.69
         
Operating expenses   1.62  2.20
Interest and other credit facility expenses   5.00  3.21
         
Total expenses   6.62  5.41
         
Average debt outstanding  $285,613  $280,590 
Portfolio turnover ratio   12.1  7.4
   
Nine months
ended
September 30,
2023
  
Nine months
ended
September 30,
2022
 
Per Share Data: (a)
   
Net asset value per Unit, beginning of period
  $10.33  $10.28 
  
 
 
  
 
 
 
Net investment income
   0.89   0.76 
Net realized and unrealized gain (loss)
   (0.31)*   0.06 
  
 
 
  
 
 
 
Net increase in Unitholders’ capital resulting from operations
   0.58   0.82 
Distributions to Unitholders:
   
From distributable earnings
   (0.27  (0.25
  
 
 
  
 
 
 
Net asset value per Unit, end of period
  $10.64  $10.85 
  
 
 
  
 
 
 
Total Return (b)(c)
   5.61  7.98
Unitholders’ capital, end of period
  $267,973  $206,003 
Units outstanding, end of period
   25,190,253   18,992,563 
  
 
 
  
 
 
 
Ratios to average net assets of Unitholders’ Capital (c):
   
Net investment income
   8.57  7.16
  
 
 
  
 
 
 
Operating expenses
   2.63  3.31
Interest and other credit facility expenses
   7.11  5.43
  
 
 
  
 
 
 
Total expenses
   9.74  8.74
  
 
 
  
 
 
 
Average debt outstanding
  $274,782  $291,045 
Portfolio turnover ratio
   15.9  8.1
 
(a)
Calculated using the average unitsUnits outstanding method. Weighted average unitsUnits outstanding for the sixnine months ended JuneSeptember 30, 2023 and JuneSeptember 30, 2022 were 23,512,65124,077,997 and 17,342,279,17,898,419, respectively.
(b)
Calculated as the change in NAVnet asset value (“NAV”) per unitUnit during the period plus distributions declared per unit,Unit, divided by the beginning NAV per unit.Unit. Total return does not include a sales load.
(c)
Not annualized
for
periods less than one year.
*
Includes the impact of the different unitUnit amounts used in calculating per unitUnit data as a result of calculating certain per unitUnit data based upon the weighted average unitsUnits outstanding during the period and certain per unitUnit data based on the unitsUnits outstanding as of a period end.
29

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June
September 30, 2023
(in thousands, except unit amounts)
 
Note 9. Subsequent Events
The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure
On October 13, 2023, the Company delivered a capital drawdown notice to its investor, an investment fund created by a financial institution unaffiliated with the Company (the “Access Fund”), relating to the sale of approximately 1,500,000 Units, for an aggregate offering price of $16,300. The sale closed on October 27, 2023.
The sale of Units is being made pursuant to a subscription agreement (the “Subscription Agreement”) and the LLC Agreement entered into by the Company and the Access Fund. Under the terms of the Subscription Agreement and the LLC Agreement, the Access Fund is required to fund drawdowns to purchase Units up to the amount of its capital commitment on an
as-needed
basis with a minimum of 10 business days’ prior notice to the Access Fund.
The issuance and sale of the Units are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and Regulation D thereunder.
On October 20, 2023, the SPV entered into the third amendment (the “Amendment”) to the SPV Facility. Pursuant to the Amendment, (i) commitments to the SPV Facility were reduced from $300,000 to approximately $261,388, as may be further adjusted per the terms of the SPV Facility, (ii) the final maturity date of the SPV Facility was extended from December 31, 2023 to August 15, 2024, and (iii) the general stated interest rate of the SPV Facility was decreased from SOFR plus 2.90% with respect to advances denominated in these consolidated financial statements.U.S. dollars and CDOR plus 2.90% with respect to advances denominated in Canadian dollars to SOFR plus 2.70% with respect to advances denominated in U.S. dollars and CDOR plus 2.70% with respect to advances denominated in Canadian dollars, among other
non-material
changes.
 
30

Report of Independent Registered Public Accounting Firm
To the Unitholders’ and Board of Directors
SCP Private Credit Income BDC LLC:
Results of Review of Interim Financial Information
We have reviewed the consolidated statement
of
assets and liabilities of SCP Private Credit Income BDC LLC (and subsidiaries) (the Company), including the consolidated schedule of investments, as of JuneSeptember 30, 2023, the related consolidated statements of operations and changes in unitholders’ capital for the three-month and
six-month
nine-month periods ended JuneSeptember 30, 2023 and 2022, the related consolidated statements of cash flows for the
six-month
nine-month periods ended JuneSeptember 30, 2023 and 2022, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.
We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statement of assets and liabilities, including the consolidated schedule of investments, of the Company as of December 31, 2022, and the related consolidated statements of operations, changes in unitholders’ capital, and cash flows for the year then ended (not presented herein); and in our report dated February 28, 2023, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated statement of assets and liabilities, including the consolidated schedule of investments, as of December 31, 2022, is fairly stated, in all material respects, in relation to the consolidated statement of assets and liabilities, including the consolidated schedule of investments, from which it has been derived.
Basis for Review Results
This consolidated interim financial information is the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
/s/ KPMG LLP
New York, New York
August 8, 2023
 
/s/ KPMG LLP
New York, New York
November 7, 2023
31


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about SCP Private Credit Income BDC LLC, our current and prospective Portfolio Investments (as defined below), our industry, our beliefs and opinions, and our assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

 

our future operating results, including our ability to achieve objectives;

 

our business prospects and the prospects of our portfolio companies;

 

the impact of investments that we expect to make;

 

our contractual arrangements and relationships with third parties;

 

the dependence of our future success on the general economy and its impact on the industries in which we invest;

 

the impact of any protracted decline in the liquidity of credit markets on our business;

 

the ability of our portfolio companies to achieve their objectives;

 

the valuation of our investments in portfolio companies, particularly those having no liquid trading market;

 

market conditions and our ability to access alternative debt markets and additional debt and equity capital;

 

our expected financings and investments;

 

the adequacy of our cash resources and working capital;

 

the timing of cash flows, if any, from the operations of our portfolio companies;

 

the ability of our investment adviser to locate suitable investments for us and to monitor and administer our investments;

 

the ability of our investment adviser to attract and retain highly talented professionals;

 

the ability of our investment adviser to adequately allocate investment opportunities among the Company and its other advisory clients;

 

any conflicts of interest posed by the structure of the management fee and incentive fee to be paid to the Adviser;

 

changes in political, economic or industry conditions, relations between the United States, Russia, Ukraine and other nations, the interest rate environment or conditions affecting the financial and capital markets;

 

the escalating conflict in the Middle East;

changes in the general economy, slowing economy, rising inflation, risk of recession and risks in respect of a failure to increase the U.S. debt ceiling; and

 

our ability to anticipate and identify evolving market expectations with respect to environmental, social and governance matters, including the environmental impacts of our portfolio companies’ supply chainchains and operations.

These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

 

an economic downturn could impair our portfolio companies’ ability to continue to operate, which could lead to the loss of some or all of our investments in such portfolio companies;

 

32


a contraction of available credit and/or an inability to access the equity markets could impair our lending and investment activities;

 

interest rate volatility could adversely affect our results, particularly because we use leverage as part of our investment strategy;

 

currency fluctuations could adversely affect the results of our investments in foreign companies, particularly to the extent that we receive payments denominated in foreign currency rather than U.S. dollars; and

 

  

the risks, uncertainties and other factors we identify in Item 1A. — Risk Factors contained in our Annual Report on Form 10-K for the year ended December 31, 2022, elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the SEC.

Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described or identified in the section entitled “Item 1A. Risk Factors” and elsewhere in this report. These forward-looking statements apply only as of the date of this report. Moreover, we assume no duty and do not undertake to update the forward-looking statements.

The following analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto contained elsewhere in this Quarterly Report on Form 10-Q.

Overview

SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) was formed as a limited liability company under the laws of the State of Delaware on May 18, 2018. We have elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”), and have elected to be treated as a regulated investment company (“RIC”) for U.S. federal income tax purposes. As such, we are required to comply with various regulatory requirements, such as the requirement to invest at least 70% of our assets in “qualifying assets,” source of income limitations, RIC asset diversification requirements, and the requirement to distribute annually at least 90% of our taxable income and tax-exempt interest. In addition, we expect that all of the Company’s total portfolio will be comprised of investments in the U.S. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”).

SLR Capital Partners, LLC (the “Adviser”) serves as the Company’s investment adviser pursuant to an investment management agreement between the Company and the Adviser (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). Subject to the overall supervision of the Company’s Board of Directors (the “Board”), the Adviser is responsible for managing the Company’s business and activities, including sourcing investment opportunities, conducting research, performing diligence on potential investments, structuring our investments, and monitoring our portfolio companies on an ongoing basis through a team of investment professionals. The managing members of the Adviser are Michael Gross and Bruce Spohler, who also oversee the Adviser’s investment committee. Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Administrative Coordinator supervises or provides the Company’s administrative services, including operational trade support, net asset value calculations, financial reporting, fund accounting and registrar and transfer agent services. The Administrative Coordinator also provides assistance to the Adviser in connection with communicating with investors and other persons with respect to the Company.

The Company is organized primarily for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). Certain other investors may also invest directly in the Company. For those investors who invest through the Access Fund, we expect the Access Fund will issue a pro rata interest to each investor in the Access Fund (the “Access Fund Investors”) that, with respect to each Access Fund Investor’s investment in the Access Fund, corresponds to the pro rata share of the Company’s units (the “Units”) issued by the Company to the Access Fund. We also expect that unitsUnits will only be

33


sold (i) in the U.S. only to U.S. persons who are “accredited investors” within the meaning of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and (ii) outside the U.S. in accordance with Regulation S under the Securities Act. Upon a sale of unitsUnits to an investor, we expect the Access Fund will pass its voting rights in the Company through to the Access Fund Investors.

33


The Company’s principal focus is to invest in first lien secured floating rate loans primarily to upper middle market private leveraged companies (generally, loan sizes of $100 million to $300 million to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25 million and $100 million) that have significant free cash flow and are in non-cyclical industries in which the Adviser has direct experience. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in non-traditional asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. The Company expects to co-invest with other vehicles managed by the Adviser. There can be no assurance that the Company will be able to co-invest with such other funds, including as a result of legal restrictions and contractual restrictions and, as a result, the Company may not be able to meet its investment objective. The Company believes the potential scale resulting from co-investments with vehicles managed by the Adviser will provide the Company a significant advantage to source loans over other lenders that do not have the capital base to provide significant debt financing.

The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and the Company may from time to time take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act.

Recent Developments

None.On October 13, 2023, the Company delivered a capital drawdown notice to the Access Fund, relating to the sale of approximately 1.5 million of the Company’s Units, for an aggregate offering price of $16.3 million. The sale closed on October 27, 2023.

The sale of Units is being made pursuant to a subscription agreement (the “Subscription Agreement”) and the second amended and restated limited liability company agreement (the “LLC Agreement”) entered into by the Company and the Access Fund. Under the terms of the Subscription Agreement and the LLC Agreement, the Access Fund is required to fund drawdowns to purchase Units up to the amount of its capital commitment on an as-needed basis with a minimum of 10 business days’ prior notice to the Access Fund.

The issuance and sale of the Units are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and Regulation D thereunder.

On October 20, 2023, the SCP Private Credit Income BDC SPV LLC as borrower (the “SPV”), a wholly owned financing subsidiary of the Company, entered into the third amendment (the “Amendment”) to its second amended and restated senior secured revolving credit facility with JPMorgan Chase Bank, National Association acting as administrative agent (the “SPV Facility”). Pursuant to the Amendment, (i) commitments to the SPV Facility were reduced from $300 million to approximately $261.4 million, as may be further adjusted per the terms of the SPV Facility, (ii) the final maturity date of the SPV Facility was extended from December 31, 2023 to August 15, 2024, and (iii) the general stated interest rate of the SPV Facility was decreased from SOFR plus 2.90% with respect to advances denominated in U.S. dollars and CDOR plus 2.90% with respect to advances denominated in Canadian dollars to SOFR plus 2.70% with respect to advances denominated in U.S. dollars and CDOR plus 2.70% with respect to advances denominated in Canadian dollars, among other non-material changes.

Revenues

The Company’s principal focus is to invest in first lien secured floating rate loans primarily to upper middle market private leveraged companies (generally, aggregate loan sizes of $100 million to $300 million to companies with EBITDA between approximately $25 million and $100 million) that have significant free cash flow and are in non-cyclical industries in which we have direct experience. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in non-traditional asset-based loans and first lien loans to rapidly growing healthcare companies.

34


Expenses

The Company will (directly or indirectly) bear:

 

 (i)

all of its fees, costs, expenses and liabilities, all of its investment-related fees, costs, expenses and liabilities (including with respect to amounts incurred prior to the Company’s initial closing) and all of its other operating fees, costs, expenses and liabilities, including all fees, due diligence costs and other fees, costs, expenses and liabilities related to the identification, sourcing, evaluation, pursuit, acquisition, holding, appraisals, asset management, restructuring and disposing of investments, including all reasonable travel-related fees, costs, expenses and liabilities, including lodging and meals, all fees, costs, expenses and liabilities of legal counsel and financial and other advisers incurred in connection therewith, all fees, costs, expenses and liabilities of information technology services relating to the ongoing management of investments, and all other investment-related fees, costs, expenses and liabilities (to the extent not reimbursed by the relevant portfolio company);

 

 (ii)

all fees, costs, expenses and liabilities related to any audits or agreed upon procedures, tax forms and return preparations and filings, custodian fees and expenses, fund accounting, administrator services, financial statement preparation and reporting, web services for the benefit of Unitholders, delivery costs and expenses in connection with reporting obligations and communications and compliance services;

 

34


 (iii)

all fees, costs, expenses and liabilities relating to insurance policies (including director and officer liability insurance) maintained by or for the Company, including in respect of Portfolio Investments and/or personnel of the Adviser, the Administrative Coordinator and their affiliates;

 

 (iv)

other administrative fees, costs, and liabilities;

 

 (v)

all fees, costs, expenses and liabilities of brokers, transaction finders and other intermediaries, including brokerage commissions and spreads, and all other transaction-related fees, costs, expenses and liabilities, including reverse break-up fees;

 

 (vi)

all fees, costs, expenses and liabilities relating to derivatives and hedging transactions;

 

 (vii)

all principal amounts of, and interest expense on, borrowings and guarantees, and all other fees, costs, expenses and liabilities arising out of borrowings and guarantees, including the arranging and maintenance thereof, whether incurred by the Company or incurred or facilitated by a special purpose vehicle that makes Portfolio Investments;

 

 (viii)

Management Fees;Fees and incentive fees;

 

 (ix)

Administration Fees;

 

 (x)

all fees, costs, expenses and liabilities incurred through the use or engagement of Service Providers;

 

 (xi)

all taxes, fees, penalties and other governmental charges levied against the Company and all fees, costs, expenses, penalties and liabilities related to tax compliance;

 

 (xii)

all fees, costs, expenses and liabilities of the Company’s legal counsel related to extraordinary matters, including expenses for any dispute resolution (including litigation and regulatory-related legal expenses);

 

 (xiii)

all fees, costs, expenses and liabilities relating to legal and regulatory filings, including securities law filings relating to Portfolio Investments;

 

35


 (xiv)

all fees, costs, expenses and liabilities related to the Company’s indemnification or contribution obligations;

 

 (xv)

all fees, costs, expenses and liabilities for subscription services (to the extent such subscription is required by the general partner of the Access Fund);

 

 (xvi)

any required regulatory filings and related legal fees;

 

 (xvii)

all fees, costs, expenses and liabilities ofrelated to liquidating the Company;

 

 (xviii)

transfer agent services; and

 

 (xix)

any other fees, costs, expenses and liabilities not specifically assumed by the Adviser or the Administrative Coordinator.

In addition, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company set forth in clauses (ii)-(iv) and the operating expenses included in sub-clauses (xiii) and (xvi) related to U.S. regulatory bodies above borne by the Company (directly or indirectly) will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400 million in Commitments,capital commitments (“Commitments”), an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1.25 million, or (B) if the Company has greater than $400 million in Commitments, $2.25 million. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. Solely by way of example, if Commitments equal $350 million, the Operating Expense Cap will be equal to $2.125 million. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder.

35


Additionally, the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the net asset value of the Company.

The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company. The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $0.5 million. Accordingly, $0.3 million of offering expenses were charged to capital and $0.1 million of organizational costs were expensed in 2019.

Portfolio and Investment Activity

During the three months ended JuneSeptember 30, 2023, we invested $35.8$19.2 million across 1411 portfolio companies. This compares to investing $30.7$66.1 million in 2228 portfolio companies for the three months ended JuneSeptember 30, 2022. Investments sold or prepaid during the three months ended JuneSeptember 30, 2023 totaled $41.4$28.7 million versus $12.3$4.7 million for the three months ended JuneSeptember 30, 2022.

At JuneSeptember 30, 2023, our portfolio consisted of 5453 portfolio companies and was invested 98.5%97.4% directly in senior secured loans and 1.5%2.6% in common equity/equity interests/warrants, in each case, measured at fair value versus 5559 portfolio companies invested >99.9%99.9% directly in senior secured loans and <0.1% in common equity/equity interests/warrants at JuneSeptember 30, 2022.

At JuneSeptember 30, 2023, 97.1% of our income producing investment portfolio was floating rate and 2.9% was fixed rate, measured at fair value. At JuneSeptember 30, 2022, 97.1%97.4% of our income producing investment portfolio was floating rate and 2.9%2.6% was fixed rate, measured at fair value.

36


Critical Accounting Policies

The preparation of consolidated financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies. Within the context of these critical accounting policies and disclosed subsequent events herein, we are not currently aware of any other reasonably likely events or circumstances that would result in materially different amounts being reported.

Valuation of Portfolio Investments

In December 2020, the SEC adopted new Rule 2a-5 under the 1940 Act addressing fair valuation of fund investments. The new rule sets forth requirements for good faith determinations of fair value, as well as for the performance of fair value determinations, including related oversight and reporting obligations. The new rule also defines “readily available market quotations” for purposes of the definition of “value” under the 1940 Act, and the SEC noted that this definition will apply in all contexts under the 1940 Act. The Company complies with Rule 2a-5’s valuation requirements.

The Company conducts the valuation of its assets, pursuant to which the Company’s net asset value (the “NAV”) is determined, at all times consistent with GAAP and the 1940 Act. The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 under the 1940 Act; and (6) maintain recordkeeping requirements under Rule 2a-5.

36


It is anticipated that in respect of many of the Company’s assets, readily available market quotations will not be obtainable and that such assets will be valued at fair value. A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation.

For purposes of calculating the NAV, the Company’s assets will generally be valued as described in Note 2(b) to the Company’s Consolidated Financial Statements.

Leverage

The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company expects to employ leverage and otherwise incur indebtedness with respect to theits portfolio both on a recourse and non-recourse basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio as of August 2, 2018. In connection with their subscriptions of the Units, our Unitholders were required to acknowledge our ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser will be borne by our Unitholders. As of JuneSeptember 30, 2023, the Company had $263.3$253.8 million of senior securities, for an asset coverage ratio of 201.5%205.6%.

37


Taxation as a RIC

The Company elected to be treated as a RIC under Subchapter M of the Code and intends to qualify for taxation as a RIC annually. As a RIC, the Company generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that it timely distributes to Unitholders as dividends. In order to qualify for taxation as a RIC, the Company is required, among other things, to be diversified at each quarter end and to timely distribute to its Unitholders at least 90% of investment company taxable income, as defined by the Code, for each year. There is no guarantee the Company will be able to maintain its status as a RIC. Depending on the level of taxable income earned in a given tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a nondeductible 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company will accrue an estimated excise tax, if any, on estimated excess taxable income.

Recent Accounting Pronouncements

None.

37


Results of Operations

Results are shown for the three and sixnine months ended JuneSeptember 30, 2023 and JuneSeptember 30, 2022:

Investment Income

For the three and sixnine months ended JuneSeptember 30, 2023, gross investment income totaled $15.3$15.8 million and $30.1$45.9 million, respectively. For the three and sixnine months ended JuneSeptember 30, 2022, gross investment income totaled $9.6$11.8 million and $18.3$30.1 million, respectively. The comparative increase in gross investment income is due to an increase in the average size of the income-producing portfolio as well as the impact of higher interest rates.

Expenses

Expenses totaled $8.7$8.4 million and $16.0$24.4 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2023, of which $2.8$2.5 million and $3.4$5.9 million, respectively, were management, incentive and administration fees and $5.7 million and $12.1$17.8 million, respectively, were interest and other credit facility expenses. Administrative services, organization and other general and administrative expenses totaled $0.2 million and $0.5$0.7 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2023. Expenses totaled $5.2$6.7 million and $9.8$16.5 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2022, of which $1.7$2.1 million and $3.5$5.6 million, respectively, were management, incentive and administration fees and $3.2$4.5 million and $5.8$10.3 million, respectively, were interest and other credit facility expenses. Administrative services, organization and other general and administrative expenses totaled $0.2 million and $0.5$0.7 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2022. Expenses generally consist of management fees, administration fees, performance-based incentive fees, insurance, legal expenses, directors’ expenses, audit and tax expenses and other general and administrative expenses. Interest and other credit facility expenses generally consist of interest, unused fees, agency fees and loan origination fees, if any, among others. The comparative increase in expenses is mainly due to higher index rates on our revolving credit facilities.

Net Investment Income

The Company’s net investment income totaled $6.6$7.4 million and $14.1$21.5 million, or $0.34$0.29 and $0.60$0.89 per average unit, respectively, for the three and sixnine months ended JuneSeptember 30, 2023. The Company’s net investment income totaled $4.4$5.1 million and $8.5$13.5 million, or $0.25$0.27 and $0.49$0.76 per average unit, respectively, for the three and sixnine months ended JuneSeptember 30, 2022.

38


Net Realized Gain (Loss)

The Company had investment sales and prepayments totaling approximately $41.4$28.7 million and $68.8$97.4 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2023. Net realized gain over the same periods totaled $0 and $0.1 million, and $0, respectively. The Company had investment sales and prepayments totaling approximately $12.3$4.7 million and $33.8$38.5 million, respectively, for the three and sixnine months ended JuneSeptember 30, 2022. Net realized gain (loss) over the same periods totaled $0 and $0, respectively.

Net Change in Unrealized Gain (Loss)

For the three and sixnine months ended JuneSeptember 30, 2023, net change in unrealized gain (loss) on the Company’s assets totaled $2.4($0.1) million and ($8.1)8.3) million, respectively. Net unrealized gainloss for the three months ended June 30, 2023 was primarily due to appreciation on our investments in SLR-AMI Topco Blocker, LLC, World Insurance Associates, LLC and Fertility (ITC) Investment Holdco, LLC, among others, partially offset by depreciation on our investments in Spectrum Pharmaceuticals, Inc., among others. Net unrealized loss for the six months ended JuneSeptember 30, 2023 was primarily due to depreciation on our investments in Amerimark Intermediate Holdings, LLC and TAUC Management,Peter C. Foy & Associates Insurance Services, LLC, among others, partially offset by appreciation on our investments in SLR-AMI Topco Blocker,Alimera Sciences, Inc. and GSM Acquisition Corp., among others. Net unrealized loss for the nine months ended September 30, 2023 was primarily due to depreciation on our investments in Oldco AI, LLC (f/k/a Amerimark), TAUC Management, LLC and Peter C. Foy & Associates Insurance Services, LLC, among others, partially offset by appreciation on our investments in World Insurance Associates, LLC, iCIMS, Inc. and Pinnacle Treatment Centers, Inc., among others. For the three and sixnine months ended JuneSeptember 30, 2022, net change in unrealized gain (loss) on the Company’s assets totaled ($0.3)$0.4 million and $0.5$0.9 million, respectively. Net unrealized lossgain for the three months ended JuneSeptember 30, 2022 was primarily due to the reversal of previously recognized unrealized appreciation in the value of SOC Telemed, Inc., as well as depreciation on our investments in World Insurance Associates, LLC and Foundation Consumer Brands, LLC,Arcutis Biotherapeutics, Inc., among others, partially offset by depreciation on our investments in Apex Service Partners, LLC and Rubius Therapeutics, Inc., among others. Net unrealized gain for the nine months ended September 30, 2022 was primarily due to appreciation on our investments in ACRES Commercial Mortgage, LLC, High Street Buyer,Arcutis Biotherapeutics, Inc. and Ivy Fertility Services, LLC, among others. Net unrealized gain for the six months ended June 30, 2022 was primarily due

38


to appreciation on our investments in Apex Service Partners, LLC, ACRES Commercial Mortgage, LLC and Kid Distro Holdings, LLC, among others, partially offset by depreciation on our investments in World Insurance Associates,Apex Service Partners, LLC, Rubius Therapeutics, Inc. and Foundation Consumer Brands, LLC,GSM Acquisition Corp., among others, as well as the reversal of previously recognized appreciation in Community Brands ParentCo, LLC.

Net Increase in Unitholders’ Capital Resulting From Operations

For the three and sixnine months ended JuneSeptember 30, 2023, the Company had a net increase in Unitholders’ capital resulting from operations of $9.0$7.3 million and $6.0$13.3 million, respectively. For the same period, income per average unit was $0.36$0.29 and $0.25,$0.55, respectively. For the three and sixnine months ended JuneSeptember 30, 2022, the Company had a net increase in Unitholders’ capital resulting from operations of $4.2$5.4 million and $9.0$14.4 million, respectively. For the same period, income per average unit were $0.24$0.29 and $0.52,$0.81, respectively.

Financial Condition, Liquidity and Capital Resources

Our primary uses of cash are for (i) investments in portfolio companies and other investments to comply with certain portfolio diversification requirements, (ii) the cost of operations (including paying the Adviser), (iii) debt service of any borrowings, and (iv) cash distributions to our Unitholders.

Equity

During the period March 12, 2019 (commencement of operations) to JuneSeptember 30, 2023, on a net basis, the Company sold and issued 25,190,253 common unitsUnits at an average price of $10.38 per unit,Unit, for net proceeds of $261.5 million. All of our outstanding unitsUnits were issued and sold in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. Unfunded equity capital commitments totaled $64.5 million at JuneSeptember 30, 2023.

Debt

Revolving credit facility due December 2023 (theSPV Facility”)—On February 27, 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into a $100 million SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up

39


to $400 million. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75 million. On February 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100 million. On July 16, 2021, the Company entered into an amended and restated SPV Facility, which increased commitments to $125 million, and on August 18, 2021 entered into a second amended and restated SPV Facility which increased commitments to $200 million and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275 million. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300 million and changed the interest rate to a SOFR-based calculation. As of JuneSeptember 30, 2023, there were $236.5$223.8 million of borrowings outstanding under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted.

Revolving credit facility due December 2023 (theSubscription Facility”)—During the first quarter of 2019, the Company established the $35.0 million Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35.0 million to $50.0 million. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50.0 million to $75.0 million and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100 million and extended the

39


maturity date to December 31, 2022. On December 28, 2022, the Company entered into a first amendment to the amended and restated loan and security agreement, changing the stated interest rate on the Subscription Facility to SOFR plus 2.80%, reducing commitments to $75 million and extending the maturity date to December 31, 2023. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of JuneSeptember 30, 2023, there were $26.8$30.0 million of borrowings outstanding under the Subscription Facility.

Cash Equivalents

We deem certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities as cash equivalents. The Company makes purchases that are consistent with its purpose of making investments in securities described in paragraphs 1 through 3 of Section 55(a) of the 1940 Act. From time to time, including at or near the end of each fiscal quarter, we consider using various temporary investment strategies for our business. One strategy includes taking proactive steps by utilizing cash equivalents as temporary assets with the objective of enhancing our investment flexibility pursuant to Section 55 of the 1940 Act. More specifically, from time-to-time we may purchase U.S. Treasury bills or other high-quality, short-term debt securities at or near the end of the quarter and typically close out the position on a net cash basis subsequent to quarter end. We may also utilize repurchase agreements or other balance sheet transactions, including drawing down on our credit facilities, as deemed appropriate. The amount of these transactions or such drawn cash for this purpose is excluded from total assets for purposes of computing the asset base upon which the management fee is determined. We held no cash equivalents at JuneSeptember 30, 2023.

Contractual Obligations

We have entered into certain contracts under which we have material future commitments. We have entered into the Investment Management Agreement with the Adviser in accordance with the 1940 Act. Under the Investment Management Agreement, the Company will pay the Adviser the Management Fee and the Incentive Fee, and the Administrative Coordinator the Administration Fee. Under the Investment Management Agreement, the Administrative Coordinator may engage or delegate certain administrative functions to third parties or affiliates on behalf of the Company. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain on-going, routine, non-investment-related administrative services for the Company, (ii) the coordination of various third partythird-party services needed or required by the Company, and (iii) certain Unitholder servicing functions.

40


A summary of our significant contractual payment obligations is as follows as of JuneSeptember 30, 2023:

 

Payments due by Period as of June 30, 2023
(dollars in millions)

 

Payments due by Period as of September 30, 2023
(dollars in millions)

Payments due by Period as of September 30, 2023
(dollars in millions)

 
  Total   Less than
1 year
   1-3 years   3-5 years   More than
5 years
   Total   Less than
1 year
   1-3 years   3-5 years   More than
5 years
 

Credit facilities (1)

  $263.3   $263.3   $—     $—     $—    $253.8   $253.8   $—     $—     $—  

 

(1)

At JuneSeptember 30, 2023, we had a total of $48.2$45.0 million of unused borrowing capacity under our credit facilities, subject to borrowing base limits.

If any of the contractual obligations discussed above are terminated, our costs under any new agreements that we enter into may increase. In addition, we would likely incur significant time and expense in locating alternative parties to provide the services we expect to receive under the Investment Management Agreement. Any new investment advisory agreement would also be subject to approval by our Unitholders.

40


Off-Balance Sheet Arrangements

From time-to-time and in the normal course of business, the Company may make unfunded capital commitments to current or prospective portfolio companies. Typically, the Company may agree to provide delayed-draw term loans or, to a lesser extent, revolving loan or equity commitments. These unfunded capital commitments always take into account the Company’s liquidity and cash available for investment, portfolio and issuer diversification, and other considerations. Accordingly, the Company had the following unfunded capital commitments at JuneSeptember 30, 2023 and December 31, 2022, respectively:

 

   June 30, 2023   December 31,
2022
 

(in millions)

 

Outset Medical, Inc.

  $11.9   $11.9 

Human Interest Inc.

   6.8    6.8 

Vessco Midco Holdings, LLC

   3.4    5.0 

Glooko, Inc.

   3.2    3.2 

Arcutis Biotherapeutics, Inc.

   3.1    3.1 

Ardelyx, Inc.

   2.7    2.7 

iCIMS, Inc.

   2.7    3.9 

Cerapedics, Inc.

   2.4    2.4 

High Street Buyer, Inc.

   2.0    2.8 

RxSense Holdings, LLC

   1.6    1.6 

Pediatric Home Respiratory Services, LLC

   1.5    2.4 

Enverus Holdings, Inc.

   1.5    1.2 

Maurices, Incorporated

   1.5    2.7 

RSC Acquisition, Inc.

   1.4    10.3 

Nexus Intermediate III, LLC (Vortex)

   1.3    1.3 

Meditrina, Inc.

   1.2    1.2 

Spectrum Pharmaceuticals, Inc.

   1.2    3.0 

Kid Distro Holdings, LLC

   1.1    1.1 

GSM Acquisition Corp.

   1.1    1.1 

Foundation Consumer Brands, LLC

   1.0    1.0 

Basic Fun, Inc.

   1.0    1.2 

Ultimate Baked Goods Midco LLC

   0.7    0.6 

Orthopedic Care Partners Management, LLC

   0.7    2.2 

Southern Orthodontic Partners Management, LLC

   0.7    2.6 

Kaseya, Inc.

   0.6    1.3 

MRI Software LLC

   0.6    0.6 

ENS Holdings III Corp. & ES Opco USA LLC

   0.6    0.2 

SunMed Group Holdings, LLC

   0.5    0.2 

Transportation Insight, LLC

   0.4    1.8 

World Insurance Associates, LLC

   0.4    0.1 

TAUC Management, LLC

   0.4    0.4 

Amerimark Intermediate Holdings, LLC

   0.2    —   

CC SAG Holdings Corp. (Spectrum Automotive)

   0.2    6.6 

Oral Surgery Partners Holdings, LLC

   —      3.3 

Plastics Management, LLC

   —      3.1 

Erie Construction Mid-west, LLC

   —      1.6 

Tilley Chemical Buyer, Inc.

   —      0.6 

Peter C. Foy & Associates Insurance Services, LLC

   —      0.6 

Pinnacle Treatment Centers, Inc.

   —      0.5 

Ivy Fertility Services, LLC

   —      0.5 

BayMark Health Services, Inc.

   —      0.5 

NAC Holdings Corporation

   —      0.5 

Apex Service Partners, LLC

   —      0.3 

All States Ag Parts, LLC

   —      0.2 
  

 

 

   

 

 

 

Total Commitments

  $59.6   $98.2 
  

 

 

   

 

 

 
   September 30,
2023
   December 31,
2022
 
(in millions) 

Outset Medical, Inc.

  $11.9   $11.9 

Human Interest Inc.

   6.8    6.8 

Arcutis Biotherapeutics, Inc.

   3.1    3.1 

Ardelyx, Inc.

   2.7    2.7 

iCIMS, Inc.

   2.5    3.9 

Cerapedics, Inc.

   2.4    2.4 

Neuronetics, Inc.

   2.0    —   

High Street Buyer, Inc.

   1.9    2.8 

Maurices, Incorporated

   1.6    2.7 

RxSense Holdings, LLC

   1.6    1.6 

Enverus Holdings, Inc.

   1.5    1.2 

Nexus Intermediate III, LLC (Vortex)

   1.3    1.3 

Kid Distro Holdings, LLC

   1.1    1.1 

GSM Acquisition Corp.

   1.1    1.1 

Foundation Consumer Brands, LLC

   1.0    1.0 

Basic Fun, Inc.

   1.0    1.2 

Ultimate Baked Goods Midco LLC

   0.7    0.6 

Kaseya, Inc.

   0.6    1.3 

MRI Software LLC

   0.6    0.6 

 

41


   September 30,
2023
   December 31,
2022
 
(in millions) 

ENS Holdings III Corp. & ES Opco USA LLC

   0.6    0.2 

SunMed Group Holdings, LLC

   0.5    0.2 

Transportation Insight, LLC

   0.4    1.8 

Vessco Midco Holdings, LLC

   0.4    5.0 

TAUC Management, LLC

   0.4    0.4 

CC SAG Holdings Corp. (Spectrum Automotive)

   0.2    6.6 

Accession Risk Management Group, Inc.

   —      10.3 

Oral Surgery Partners Holdings, LLC

   —      3.3 

Glooko, Inc.

   —      3.2 

Plastics Management, LLC

   —      3.1 

Spectrum Pharmaceuticals, Inc.

   —      3.0 

Southern Orthodontic Partners Management, LLC

   —      2.6 

Pediatric Home Respiratory Services, LLC

   —      2.4 

Orthopedic Care Partners Management, LLC

   —      2.2 

Erie Construction Mid-west, LLC

   —      1.6 

Meditrina, Inc.

   —      1.2 

Tilley Chemical Buyer, Inc.

   —      0.6 

Peter C. Foy & Associates Insurance Services, LLC

   —      0.6 

Pinnacle Treatment Centers, Inc.

   —      0.5 

Ivy Fertility Services, LLC

   —      0.5 

BayMark Health Services, Inc.

   —      0.5 

NAC Holdings Corporation

   —      0.5 

Apex Service Partners, LLC

   —      0.3 

All States Ag Parts, LLC

   —      0.2 

World Insurance Associates, LLC

   —      0.1 
  

 

 

   

 

 

 

Total Commitments

  $47.9   $98.2 
  

 

 

   

 

 

 

The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of JuneSeptember 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments.

Distributions

Tax characteristics of all distributions will be reported to unitholders on Form 1099 after the end of the calendar year. Future quarterly distributions, if any, will be determined by our Board. We expect that our distributions to unitholders will generally be from accumulated net investment income, from net realized capital gains or non-taxable return of capital, if any, as applicable.

We have elected to be taxed as a RIC under Subchapter M of the Code. To maintain our RIC tax treatment, we must distribute at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, out of the assets legally available for distribution. In addition, although we currently intend to distribute realized net capital gains (i.e., net long-term capital gains in excess of short-term capital losses), if any, at least annually, out of the assets legally available for such distributions, we may in the future decide to retain such capital gains for investment.

42


We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a BDC, we may in the future be limited in our ability to make distributions. Also, our revolving credit facility may limit our ability to declare distributions if we default under certain provisions. If we do not distribute a certain percentage of our income annually, we will suffer adverse tax consequences, including possible loss of the tax benefits available to us as a RIC. In addition, in accordance with GAAP and tax regulations, we include in income certain amounts that we have not yet received in cash, such as contractual payment-in-kind income, which represents contractual income added to the loan balance that becomes due at the end of the loan term, or the accrual of original issue or market discount. Since we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the requirement to distribute at least 90% of our investment company taxable income to obtain tax benefits as a RIC.

With respect to the distributions to unitholders, income from origination, structuring, closing and certain other upfront fees associated with investments in portfolio companies are treated as taxable income and accordingly, distributed to unitholders.

Related Parties

We have entered into the Investment Management Agreement with the Adviser. Mr. Gross, our Chairman, Co-Chief Executive Officer and President and Mr. Spohler, our Co-Chief Executive Officer, Chief Operating Officer and board member, are managing members and senior investment professionals of, and have financial and controlling interests in, the Adviser. In addition, Mr. Kajee, our Chief Financial Officer Treasurer and SecretaryTreasurer serves as the Chief Financial Officer for the Adviser.

The Adviser may also manage other funds in the future that may have investment mandates that are similar, in whole and in part, with ours. For example, the Adviser presently serves as investment adviser to SLR Investment Corp., a publicly traded BDC, which focuses on investing in senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities, SLR HC BDC LLC, an unlisted BDC whose principal focus is to invest directly and indirectly in senior secured loans and other debt instruments typically to middle market companies within the healthcare industry, and SLR Private Credit BDC II LLC, an unlisted BDC whose principal focus is to invest in first

42


lien senior secured floating rate loans primarily to upper middle market leveraged companies with EBITDA between approximately $25 million and $250 million that have significant free cash flow and are in non-cyclical industries in which the Adviser has significant experience. In addition, Michael S. Gross, our Chairman, Co-Chief Executive Officer and President, Bruce Spohler, our Co-Chief Executive Officer and Chief Operating Officer, and Shiraz Y. Kajee, our Chief Financial Officer, serve in similar capacities for SLR Investment Corp., SLR HC BDC LLC and SLR Private Credit BDC II LLC. The Adviser and certain investment advisory affiliates may determine that an investment is appropriate for us and for one or more of those other funds. In such event, depending on the availability of such investment and other appropriate factors, the Adviser or its affiliates may determine that we should invest side-by-side with one or more other funds. Any such investments will be made only to the extent permitted by applicable law and interpretive positions of the SEC and its staff, and consistent with the Adviser’s allocation procedures. On June 13, 2017, the Adviser received an exemptive order that permits the Company to participate in negotiated co-investment transactions with certain affiliates, in a manner consistent with the Company’s investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to various conditions (the “Order”). If the Company is unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although the Adviser’s investment professionals will endeavor to allocate investment opportunities in a fair and equitable manner, the Company and its Unitholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of the Adviser. In addition, we have adopted a formal code of ethics that governs the conduct of our officers and directors. Our officers and directors also remain subject to the duties imposed by both the 1940 Act and the Delaware Limited Liability Company Act.

43


Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to financial market risks, including changes in interest rates. Uncertainty with respect to the rising interest rates, inflationary pressures, risks in respect of a failure to increase the U.S. debt ceiling or a downgrade in the U.S. credit rating, the warwars between Ukraine and Russia and health epidemics and pandemics introduced significant volatility in the financial markets, and the effects of this volatility hashave materially impacted and could continue to materially impact our market risks. Because we fund a portion of our investments with borrowings, our net investment income is affected by the difference between the rate at which we invest and the rate at which we borrow. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In a low interest rate environment, including a reduction of LIBOR or SOFR to zero, the difference between the total interest income earned on interest earning assets and the total interest expense incurred on interest bearing liabilities may be compressed, reducing our net interest income and potentially adversely affecting our operating results. Conversely, in a rising interest rate environment, such as the current economic environment, such difference could potentially increase thereby increasing our net investment income. During the sixnine months ended JuneSeptember 30, 2023, certain investments in our investment portfolio had floating interest rates. These floating rate investments were primarily based on floating LIBOR or SOFR and typically have durations of one to three months after which they reset to current market interest rates. Additionally, some of these investments have floors. The Company also has revolving credit facilities that are generally based on floating LIBOR or SOFR. Assuming no changes to our balance sheet as of JuneSeptember 30, 2023 and no new defaults by portfolio companies, a hypothetical one percent decrease in LIBOR or SOFR on our comprehensive floating rate assets and liabilities would decrease our net investment income by approximately eight cents per average unit over the next twelve months. Assuming no changes to our balance sheet as of JuneSeptember 30, 2023 and no new defaults by portfolio companies, a hypothetical one percent increase in LIBOR or SOFR on our comprehensive floating rate assets and liabilities would increase our net investment income by approximately eight cents per average unit over the next twelve months. However, we may hedge against interest rate fluctuations from time-to-time by using standard hedging instruments such as futures, options, swaps and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in any benefits of certain changes in interest rates with respect to our portfolio of investments. At JuneSeptember 30, 2023, we have no interest rate hedging instruments outstanding on our balance sheet.

 

Increase (Decrease) in LIBOR/SOFR

   (1.00%)   1.00

Increase in Net Investment Income Per Unit Per Year

  $(0.08 $0.08 

43


Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As of JuneSeptember 30, 2023 (the end of the period covered by this report), our management, including our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Act of 1934, Act)as amended (the “Exchange Act”). Based on that evaluation, our management, including the Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.

44


(b) Changes in Internal Controls Over Financial Reporting

Management has not identified any change in the Company’s internal control over financial reporting that occurred during the secondthird quarter of 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We and our consolidated subsidiaries are not currently subject to any material pending legal proceedings threatened against us. From time to time, we may be a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our rights under contracts with our portfolio companies. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our business, financial condition or results of operations beyond what has been disclosed within these financial statements.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” in the February 28, 2023 filing of the Annual Report on Form 10-K, which could materially affect our business, financial condition and/or operating results. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. Other than the risk factorfactors set forth below, there have been no material changes during the three months ended JuneSeptember 30, 2023 to the risk factors discussed in “Risk Factors” in the February 28, 2023 filing of our Annual Report on Form 10-K.

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties could have a material adverse effect on us, the Adviser and our portfolio companies.

Cash not held in custody accounts and held by us, our Adviser and by our portfolio companies in non-interest-bearing and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, we, our Adviser, or our portfolio companies could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect our, our Adviser’s and our portfolio companies’ business, financial condition, results of operations, or prospects.

44


Although we and our Adviser assess our and our portfolio companies’ banking and financing relationships as we believe necessary or appropriate, our and our portfolio companies’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we, our Adviser or our portfolio companies have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services

45


industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we, our Adviser or our portfolio companies have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us, our Adviser, or our portfolio companies to acquire financing on acceptable terms or at all.

The alternative reference rates that have replaced LIBOR in our credit arrangements and other financial instruments may not yield the same or similar economic results as LIBOR over the life of such transactions.

The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to our portfolio companies.

The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on JuneSeptember 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances.

In the United States, the Secured Overnight Financing Rate (“SOFR”)SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions.

As of the filing date of this Quarterly Report on Form 10-Q, many of our loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed, one-month and three-month CME Group traded SOFR futures contracts and, in some cases, over-the-counter SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR.

46


There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, our loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, our loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on our loans may not be fully realized and our loans may be subject to increased pricing volatility and market risk.

Item 2. Unregistered Sales of Equity Securities, and Use of Proceeds,

and Issuer Purchases of Equity Securities

There were no unregistered sales of equity securities other than those already disclosed in certain Form

8-Ks
filed with the SEC.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

47


Item 5. Other Information
Rule
10b5-1
Trading Plans
During the fiscal quarter ended JuneSeptember 30, 2023, none
of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)
adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule
10b5-1
trading arrangement” as defined in Item 408(c) of Regulation
S-K.
 

45
48


Item 6. Exhibits

The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:

 

3.1  Certificate of Formation(1)Formation(1)
3.2  Second Amended and Restated Limited Liability Company Agreement(2)Agreement(2)
4.1  Form of Subscription Agreement(1)Agreement(1)
31.1  Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
31.2  Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
31.3  Certification of Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
32.1  Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2  Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.3  Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS  Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded with the Inline XBRL document.
101.SCH  Inline XBRL Taxonomy Extension Schema Document*
101.CAL  Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF  Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB  Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE  Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104  Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

*

Filed herewith.

(1)

Previously filed as an exhibit to Amendment No. 1 to the Registrant’s Registration Statement on Form 10 (File No. 000-55955) filed with the SEC on August 24, 2018.

(2)

Previously filed in connection with the Registrant’s report on Form 10-K filed on February 20, 2020.

 

4649


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 8,November 7, 2023.

 

SCP PRIVATE CREDIT INCOME BDC LLC
By: 

/s/ MICHAEL S. GROSS

 

Michael S. Gross

Co-Chief Executive Officer

(Principal Executive Officer)

By: 

/s/ BRUCE J. SPOHLER

 

Bruce J. Spohler

Co-Chief Executive Officer

(Principal Executive Officer)

By: 

/s/ SHIRAZ Y. KAJEE

 

Shiraz Y. Kajee

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

4750